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ABSTRACT: A second-generation synthesis of (−)-luminacin D based on an early stage introduction of the trisubstituted
epoxide group is reported, allowing access to the natural product in an improved yield and a reduced number of steps (5.4%, 17
steps vs 2.6%, 19 steps). A full account of the optimization work is provided, with the reversal of stereoselection in the formation
of the C4 alcohol in equally excellent diastereoselectivity as the key improvement.
1. INTRODUCTION
Angiogenesis is deﬁned as the formation of new blood vessels
from the pre-existing vascular network.1 Through its involve-
ment in numerous pathologies, including tumor growth and
metastasis, angiogenesis and its associated regulation mecha-
nisms have emerged as promising targets in drug discovery. In
particular, remarkable eﬀorts have been directed toward the
identiﬁcation of angiogenic modulators among the natural
products.2,3
The luminacin family of natural products, originally isolated
from bacterial fermentation, contains numerous members that
have been shown to exhibit potent antiangiogenic activity in
several assays. Wakabayashi et al. notably demonstrated that
luminacins operate by blocking the initial stages of the capillary
tube formation in vitro, with luminacin D 1a (Chart 1) being
the most active among the 12 members tested.4 Later on,
additional in vivo studies using luminacin C2 1b revealed that
this molecule eﬀectively inhibited the phosphorylation activity
of Src tyrosine kinases and was found to exert its unique mode
of action by disrupting Src mediated protein−protein
interactions.5,6 Src tyrosine kinases play key roles in the
regulation of numerous processes associated with angiogenesis,
including growth, diﬀerentiation, migration, and survival.7 In
addition, luminacin C2 was also found to inhibit breast cancer
cell invasion and metastasis in vitro by disrupting the AMAP1-
cortactin binding (protein−protein interactions).8 The recent
isolation of two cancer cell migration inhibitors of similar
structure (migracins A and B, 1c, 1d) highlighted once more
the therapeutic potential of these molecules.9
Despite its promising antiangiogenic activity as revealed by
the original work of Wakabayashi, luminacin D has been less
extensively studied in comparison with some other members of
its family, and little information can be found regarding its
mode of action and biological functions. To obtain further
material to enable further biological investigations, chemical
synthesis is the most eﬃcient way given the modest yield from
extraction (and the fact that a new extraction campaign would
be required).
Apart from our recent contribution,10 so far there have been
four reported syntheses of luminacin derivatives,11−15 each
presenting shortcomings in terms of length or selectivity. In
particular, the eﬃciency of three from these four syntheses was
dramatically compromised by the low or undesired stereo-
selectivity associated with the epoxidation step which, in
addition, in each case took place at a late stage of the synthesis.
In this context, we achieved a highly diastereoselective synthesis
of (−)-luminacin D in 19 steps.10 As shown in Scheme 1, our
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synthetic approach relied on the stereoselective introduction of
the epoxide moiety at an early stage of the synthesis starting
from the enantiopure sulfoxide 5, and subsequently to utilize
the chirality of the epoxide group in 4 for the diastereoselective
completion of the aliphatic fragment. This was achieved via a
chelation-controlled allylation procedure of the enantiopure α-
epoxy aldehyde 4a, which proceeded in excellent yield and
diastereoselectivity. Unfortunately, the reaction led to the
formation of the undesired diastereoisomer 6, and thus an
inversion of the obtained alcohol stereocenter was required to
complete the synthesis. As further shown in the retrosynthetic
analysis, the formation of Luminacin D 1a was realized via
arylation of the fully functionalized fragment 2, whose
construction was envisaged via spontaneous hemiacetal
formation and syn-aldol reaction from the key compound 3.
A full account of the diﬀerent approaches for the formation of
the cyclic hemiacetal moiety, and further optimizations of
several other steps are disclosed here. In particular, this includes
our eﬀorts toward the development of a methodology that
resulted in direct access to the key intermediate 3 from 4.
2. RESULTS AND DISCUSSION
Synthesis of the Epoxide Precursor (Ester-sulfoxide
9). Starting from the α-sulfoxy-esters 5, we initially investigated
the one-pot Knoevenagel procedure described by Tanikaga et
al.16 in order to access to the desired (E)-alkenes 8Tol and
(±)-8Ph. This method proved unsuccessful when applied to our
substrates (recovery of starting material). Hence, as described
in our previous communication,10 the formation of racemic and
enantiopure α,β-unsaturated (E)-alkenes (±)-8Ph and 8Tol was
then accomplished in 2 steps from the corresponding β-sulfoxy-
ester, as shown in Scheme 2. At ﬁrst, following a known
procedure,17 an aldol-type condensation of 5 with propanal led
to the β-hydroxy ester 7 as an impure mixture of
diastereoisomers. It was found that treatment of this mixture
with MsCl in pyridine aﬀorded alkenes 8 in excellent yield and
stereoselectivity. Further to Tanikaga’s stereochemical assign-
ment by chemical shift diﬀerences, the E conﬁguration of 8 is
now further conﬁrmed by NOE analysis (see the Supporting
Information).
The subsequent epoxidation step had been achieved in a
diastereoselective manner in our previous synthesis, using a
procedure that was adapted from De La Pradilla’s vinyl
sulfoxide methodology (Table 1, entries 1 and 2).18 The
reaction proceeded in excellent yield and diastereoselectivity
with the phenyl derivative 8Ph (90%, dr 94:6), while the same
reaction conditions applied with tolyl derivative 8Tol led to
lower yield and diastereoselectivity (77%, dr 88:12). In
addition, the product 12 was obtained in 19% yield as a
mixture of diastereoisomers (Table 1). The latter was thought
to arise from the nucleophilic attack of n-BuLi onto the Michael
intermediate 11, since an excess of n-BuLi was used compared
to t-BuOOH (5 vs 4 equiv, respectively).
We then decided to investigate modiﬁed conditions for the
epoxidation reaction. The ﬁrst experiment was carried out with
8Tol by using an excess of t-BuOOH compared to n-BuLi (entry
Scheme 1. Retrosynthetic Analysis and New Diastereoselective Methodologies Developed
Scheme 2. Synthesis of (E)-Alkenes 8
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3). Although the reaction proceeded without any formation of
12, the formation of undesired byproducts could be observed
by 1H NMR, alongside with the expected trans-epoxides syn-
9Tol and anti-9Tol. After column chromatography, the epoxides
were isolated as a mixture of diastereoisomers in moderate yield
(60%, dr syn-9Tol/anti-9Tol 95:5). A mixture of two unexpected
products was also isolated in 16% yield, which allowed their
assignment as the cis-epoxide isomers syn-10Tol and anti-10Tol.
Following this, it was found that using a 1:1 ratio of t-BuOOH
and n-BuLi, and reducing the reaction time, allowed to
minimize the formation of the cis-epoxides 10Tol (entry 4).
The trans-epoxide 9Tol was isolated in both excellent yield and
diastereoselectivity in these conditions (82%, dr syn-9Tol/anti-
9Tol 91:9). Interestingly, the replacement of n-BuLi by NaH as
base with the racemic derivative (±)-8ph resulted in promoting
the formation of cis-isomers 10ph, with a good selectivity toward
the syn-epoxide (±)-syn-10ph (entry 5). The same outcome was
observed when an excess of NaH compared to t-BuOOH was
used with the tolyl derivative 8Tol (entry 6). The epoxidation
reaction was carried out on a 3 g scale (10 mmol) with the tolyl
derivative 8Tol using the optimized conditions, and enabled
isolation of the expected trans-epoxides 9Tol in a slightly
improved yield and diastereoselectivity compared to our earlier
procedure (entry 7, 82%, dr syn/anti 92:8 vs 77% dr syn/anti
88:12). A minor quantity of the cis-epoxides 10Tol was also
obtained after separation (<2% yield).
The assignment of conﬁguration of all the epoxide
stereomers was achieved by a combination of X-ray crystallo-
graphic analysis and a chemical correlation experiment. The
conﬁguration of the crystalline C3 (“pseudo”-) epimers syn-9Tol
and (±)-syn-10Ph was established by X-ray analysis (see the
Supporting Information), as the syn-isomers for both 9 and 10
crystallized as pure diastereomers. The stereochemical relation-
ship between the syn- and anti-epoxides was established by the
oxidation (Scheme 3) of a mixture of isomers syn-10Tol and
anti-10Tol (dr ∼ 1:1), which led to a single sulfone 13 (as
observed by 1H NMR), which allowed unambiguous assign-
ment of anti-10Tol as the cis-anti-epoxide (and by inference, also
that of anti-10Ph).
Synthesis of the Intermediate 3: The Diastereoselec-
tive Reduction Approach. As already mentioned, we
previously reported the development of a chelation-controlled
allylation methodology, which, when applied to aldehydes
possessing an α-oxygenated center, proceeded with excellent
diastereoselectivity.10 The selectivity outcome was found
consistent with the formation of a 1,3-chelated transition
state, in which facial selectivity is dictated by a Cornforth−
Evans (CE) type model. With the aim of developing a
complementary approach to the aforementioned allylation step,
our investigations were directed toward a chelation-mediated
reduction involving 1,3-keto esters such as 4b, in which the
stereoselection would be equally predicted by the CE model.
Hence, by invoking 14, hydride attack of the least congested Si-
face would directly lead to the key intermediate 3 (Scheme 4).
Table 1. Optimization of the Epoxidation Reactioni
entry Ar. base (equiv) t-BuOOH (equiv) t (h) dr syn-9/anti-9/syn-10/anti-10a overall yield (%)b yield 9 (%)b yield 10 (%)b
1c Ph n-BuLi (5) 4d 0.4 94:6:e:e 89 89 f
2c Tol n-BuLi (5) 4d 0.4 88:12:e:e 77 77 f
3 Tol n-BuLi (4) 4.9−6g 1.5 72:4:16:8 91 60 16
4 Tol n-BuLi (3) 3d 0.4 81:8:6:6 88 82 h
5 Ph NaH (2.5) 3.2−3.9g 0.4 35:4:54:7 78 23 53
6 Tol NaH (3.2) 3d 0.4 45:2:50:3 78 h 25
7c Tol n-BuLi (3) 3d 0.4 86:7:4:3 88 82 <2
aDetermined by 1H NMR. bIsolated yield. cReaction carried out on 3−6 g (10−20 mmol) scale. dA commercial solution of t-BuOOH in decane (5.5
M) was used. eNot detected. fTraces were observed in 1H NMR. gA commercial solution of t-BuOOH in decane (5−6 M) was used. hNot isolated.
iPreﬁxes syn/anti refer to the relative position of the sulfoxide aryl group compared to the epoxide function. Preﬁxes trans/cis (as used in the Results
and Discussion) refer to the relative arrangement of the epoxide substituents.
Scheme 3. Sulfone Formation
Scheme 4. Proposed Reduction Approach
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We were encouraged in this approach by the work of Castle et
al. regarding the selective addition of various nucleophiles to a
1,3-alkoxy ketone containing an α-OTBS substituent, which
was found to operate via a 1,3-chelation controlled transition
state combined with CE-type stabilization.19 Furthermore, a
number of methodologies for the metal-mediated diastereose-
lective reduction of β-keto esters, β-hydroxy ketones, and α-
epoxy ketones have been described, leading in general to
excellent facial selectivity.20−26
In order to simplify the optimization studies, we ﬁrst focused
on the synthesis of the β-propyl keto ester 4c, whose formation
was envisaged via acylation reaction of the sulfoxide 9Tol (Table
2). This was achieved in moderate yield, via treatment of 9Tol
with t-BuLi and subsequent trapping of the resulting oxiranyl
anion with methyl butyrate, under Barbier conditions. As these
reactions were carried out on the 92:8 syn/anti mixture, an 84%
product enantiopurity was obtained. Unfortunately, the
selective crystallization procedure of 9 as explained above was
only achieved after carrying out the experiments given in Table
2, but would give access to enantiopure material. As shown in
Table 2, several trials involving a Lewis acid to induce chelation
control during the reduction reaction were undertaken.19 As a
ﬁrst experiment, treatment of 4c with NaBH4 and MgBr2, in a
mixture of THF/DCM, gave no expected product. Instead,
these conditions resulted in the formation of the bromohydrin
17 as major product (48% isolated yield), alongside with the
reduced bromohydrin 18 as a mixture of diasteroisomers. The
anti-product 18a was isolated in 9% yield. The epoxide opening
issue was overcome by performing the reaction at 0 °C in
MeOH, leading to the exclusive formation of products 16. To
our surprise, the undesired anti-diastereoisomer 16a was
obtained as major product (dr 16a/16b 71:29, entry 2),
which is not consistent with reaction via the transition state 14
(cf. Scheme 4). Replacing MgBr2 by CaCl2 as chelating
metal21,22 resulted in a similar outcome, with 15a obtained in
good isolated yield and excellent diastereoselectivity (70%, dr
16a/16b 97:3, entry 3). Following this, the use of Et3SiH or L-
selectride as reducing agents with MgBr2 was also attempted at
−78 °C, though both conditions led to the exclusive formation
of the bromohydrin 17 (entries 4 and 5). Since the involvement
of MgBr2/CaCl2 led to undesired diastereoselectivity or
unexpected reactivity, the reduction of the ketone 4c was
attempted using L-selectride only (entry 6). This time, the
reaction proceeded in good yield and excellent diastereose-
lectivity toward the desired syn-product 16b (entry 6, 90%, dr
16a/16b 1:9). Interestingly, employing the more hindered LS-
selectride led to a drop of conversion and selectivity.
As shown in Figure 1, the selectivity observed when NaBH4/
CaCl2 and MgBr2 were used could be explained by the 1,2-
chelated transition state 19, assuming that the metal salt
catalyzes the formation formation of alkoxyborohydrides
NaBH4-n(OMe)n in MeOH.
26 The coordination between a
Ca2+ and the methoxy group of the borohydride species would,
therefore, direct the hydride attack to the Re-face, leading to the
anti-compound 16a. On the other hand, the models 20 and 21
are consistent with the selectivity observed when L- or LS-
selectride are employed, assuming that the Li cation is able to
chelate between the carbonyl groups (model 20) or between
the carbonyl group and the epoxide (model 21). Hydride attack
from the least hindered Si-face in both cases would lead to the
observed formation of the syn-compound 16b.
The relative conﬁguration of 16a and 16b was assigned by
NMR comparison with the anti-alcohol, which was obtained
after reduction of the double bond of previously synthesized 3
(Scheme 5). The regioselectivity of bromide mediated epoxide
opening on 4c, and the relative conﬁguration of the resulting
18a, were determined thanks to X-ray crystallographic analysis
(see the Supporting Information).
Motivated by these results, the acylation/diastereoselective
reduction procedure was then applied toward the luminacin D
Table 2. Acylation and Attempted Conditions for the Reduction Reaction
entry conditions yield 16 (%) (dr) yield 17 (%) yield 18 (%) (dr)
1 NaBH4 (1.05 equiv), MgBr2 (1.6 equiv), DCM/THF 2:1, −78 °C to rt, 3 h a 78b (48)c 22b (9)c
(dr 18a/18b 93:7)a
2 NaBH4 (1.2 equiv), MgBr2 (2 equiv), MeOH, 0 °C, 30 min 100
b (dr 16a/16b 71:29)b a a




4 Et3SiH (1.05 equiv), MgBr2 (1.6 equiv), DCM, −78 °C, 2 h a 83b (64)c a
5 L-selectride (1.05 equiv), MgBr2, (1.6 equiv), DCM, −78 °C, 2 h a 100b a
6 L-selectride (1.05 equiv), THF, −78 °C, 30 min 100b (90)c (dr 16a/16b 1:9)b a a
7 LS-selectride (1.3 equiv), THF, −78 °C, 45 min 48b (dr 16a/16b 33:67)b a a
aNot formed. bDetermined by 1H NMR. cIsolated yield.
Figure 1. Possible rationalization of the selectivity outcome.
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synthesis, using methyl but-3-eneoate 2227 and L-selectride
(Scheme 6). Since the intermediate 4b proved unstable to
puriﬁcation on silica gel (with double bond isomerization
occurring during silica gel chromatography, not shown), the
reduction reaction was attempted on the crude material,
immediately after workup. A ﬁrst experiment was conducted on
a small scale with the racemic epoxide (±)-9Ph and L-selectride
as reducing agent. The syn-α-epoxy alcohol (±)-3 was obtained
as major product in an encouraging yield (19% over 2 steps),
together with a minor quantity of the anti-diastereoisomer
(±)-7 (1% over 2 steps, separation achieved by column
chromatography). Unfortunately, the reaction proved less
eﬃcient on a 1 g scale, resulting in a drop of yield (14% for
(±)-3 over 2 steps). Several parameters, including the volatility
of intermediate 4b and the puriﬁcation issues induced by the
formation of numerous byproducts over the 2 steps, made the
process cumbersome.
Synthesis of the Intermediate 3: The Allylation
Approach. Given the moderate yield obtained with the
previous approach, the original strategy involving an allylation
reaction was reconsidered, with the aim of developing new
conditions allowing access to the opposite selectivity outcome
compared to the MgBr2-promoted allylation procedure. Given
the unexpected stereochemical outcome of the reduction
process using CaCl2 as explained above, this additive was
now used in a reinvestigation of the allylation of 4a. Hence, the
aldehyde 4a (and (±)-4a) was resynthesized through
formylation of the epoxide precursors 9, applying similar
Scheme 5. Hydrogenation of 3 To Allow Assignment of the
Relative Stereochemistry
Scheme 6. Formation of 3 and 7 via the Reduction Approach
Table 3. Formylation and Attempted Conditions for the Allylation Reaction
aDetermined by 1H NMR. bIsolated yield. cReaction carried out on 3 mmol of 4a. dBased on isolated yields. eNot isolated. fNot detected. gReaction
carried out on 5 mmol of 8 (2 steps procedure).
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conditions as used for the acylation procedure (Table 3).
Pleasingly, the reaction proceeded in an improved yield
compared to our previous procedure,10 and is generally more
eﬃcient as it can be conducted at −78 °C (instead of −120 °C)
without the need of CeCl3, which had to be dried under
vacuum prior to the reaction and made the work up diﬃcult.
We then examined the use of a modiﬁed procedure for the
allylation reaction (Table 3). The conditions of the reported
procedure (entry 1), but with CaCl2 instead of MgBr2, were
investigated ﬁrst (entry 2). Despite the poor conversion
obtained, we were pleased to notice that only the desired syn-
diastereoisomer 3 was formed during the reaction, as observed
by 1H NMR of the reaction mixture before chromatography.
Increasing the temperature, concentration, and reaction time
resulted in a better conversion, with 3 obtained in a very good
diastereoselectivity (entry 3, dr 3/7 92:8). On the basis of these
results, it was envisaged that CaCl2 might not be involved in a
chelated transition state, but would only act as a weak activator
of the reaction. To conﬁrm this hypothesis, investigations were
directed toward the use of nonchelating conditions for the
allylation reaction. A ﬁrst experiment involving the reaction of
4a with allyltrimethylsilane and a substoichiometric amount of
TBAF led to the recovery of the starting material (entry 4).28
However, the allylation of 4a occurred using the more reactive
pinacolyl allylboronate 23 in DCM, by raising the temperature
from −78 °C to rt overnight (entry 5).29 As predicted, the
nonchelation control promoted the formation of the desired
syn-diastereoisomer 3, in an excellent diastereoselectivity and
isolated yield. This result mirrors the work of Mulzer and
Prantz, who recently demonstrated that the selectivity of the
allylation of 2,2-dialkyl-3-oxopropionates could be reverted by
switching from chelation (TiCl4) to nonchelation (BF3·OEt2)
mediated allylation.30 It should be noted that both of these
Lewis acids are not compatible with the epoxide-containing
substrate 4. The optimized two-step procedure was then carried
out on a 1.5 g (5 mmol) scale of sulfoxide 9Tol (dr 92:8) (entry
6). The slow addition of t-BuLi to the mixture via syringe pump
over a period of 1 h was found to give the best results for the
formylation reaction. After column chromatography, the
aldehyde 4a was obtained in a mixture with minor impurities.
Subsequent treatment with the pinacolyl allylboronate 23 using
the optimized conditions enabled isolation of the syn-alcohol 3
as major product in 33% yield over 2 steps, together with the
minor anti-diastereoisomer 7, isolated in 1% yield. Although an
accurate dr determination was not possible by 1H NMR due to
the presence of impurities, the ratio of isolated yields of 7 and 3
is consistent with that observed on a small scale. Similar results
were obtained when the racemic phenyl epoxide (±)-9Ph was
used as starting material (entry 7).
In the context of the luminacin D synthesis, this new
procedure represents a signiﬁcant improvement compared to
the previous route reported by our laboratory, which required
two extra steps for the formation of 3, in a lower overall yield
(24% over 4 steps). The excellent substrate control of this
allylation reaction under nonchelating conditions can be
rationalized (Figure 2) by invoking the classic Cornforth−
Evans (24) or polar Felkin−Anh (25) models, assuming that
the C−O bond of the epoxide acts as the “polar substituent” in
preference to the ester.
Completion of the Aliphatic Fragment: Aldol Reaction
and Attempted Lactonization. With access to the pure
intermediate 3 (and (±)-3), the synthesis was pursued toward
the formation of aldehyde 26 (and (±)-26), which was
accomplished in two steps, following the reported procedure
(Scheme 7). The β-chiral silyl ether center on 26 oﬀered the
possibility for remote stereocontrol, which had been exploited
in the luminacin D synthesis by Shipman et al.15 However, the
use of a titanium enolate derived from an aromatic ketone
(already containing the luminacin D aliphatic moiety) only led
to modest stereocontrol (dr ∼ 2:1, in favor of the desired
isomer). Interestingly, while this type of remote stereocontrol
has been mainly investigated for Mukaiyama aldol reactions,31
we found no related investigations of the extent of remote
stereocontrol for aldol reactions involving classic N-acyl
oxazolidinone boron enolate reagents. Hence, at this juncture,
we decided to investigate this process using simpliﬁed model
compounds in order to evaluate its potential usefulness in the
luminacin D synthesis (Table 4). Aldehydes (±)-2732 and
(±)-2832 were prepared according to standard procedures and
subjected to aldol reactions with the boron enolate of 29. For
the reaction between the ethyl oxazolidinone 28a and (±)-26, a
low stereocontrol was obtained (entry 1). As predicted from
Figure 2. Cornforth−Evans (24) and polar Felkin−Anh (25) models
to explain the observed diastereoselectivity.
Scheme 7. Synthesis of Aldehyde 26
Table 4. Investigation of Remote Stereocontrol for the Aldol
Reaction
entry dr 30/31a R P
1 2:1 Me Bn
2 3:1 Me TBDPS
3 5:1 Pr TBDPS
aDetermined by 1H NMR.
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the Evans model, the major isomer contained the desired
relative stereochemistry for our purposes (see the Supporting
Information for the determination of the product relative
stereochemistry). Increasing the size of the protecting group
(as in (±)-28) led to a slight increase of the desired selectivity
(entry 2). A further increase of the steric bulk by using 29b, the
reagent required for the luminacin D synthesis, did give a
reasonable 5:1 ratio (entry 3).
With this level of selectivity obtained, this diastereoselective
aldol reaction was then performed on the racemic natural
product intermediate (±)-32 with a TBDPS protecting group
(Scheme 8). Unfortunately, a slightly diminished level of
selectivity (4:1) was obtained for the desired aldol diastereomer
(±)-33.
Given that the modest diastereoselectivity favored the
desired stereomer, a matched double diastereodiﬀerentiation
process using a chiral oxazolidinone based auxiliary was then
investigated. This approach has also been used in the luminacin
D synthesis by Maier et al.14 Hence, the enantiopure
oxazolidinone 3533 was required (Scheme 9). For atom
economy reasons, we decided to use a TES protecting group
as opposed to a TBDPS group. Initially, the racemic aldehyde
(±)-26 was engaged in Evans-aldol reaction with the acyl chiral
oxazolidinone, which led to the formation of two (among the
four possible) aldol adducts (1H NMR analysis) in a 1:1 dr. The
two isomers could be separated by preparative HPLC after TES
protection of the formed alcohol, allowing isolation of the
expected aldol product 3810 as well as the isomer 39, the latter
resulting from the aldol reaction of the oxazolidinone 35 with
the enantiomer of 26, since racemic starting material was
employed. Given the low remote stereocontrol exerted by the
alcohol chiral center as shown above, it is thought that the
auxiliary dominates the stereoselection, leading to the C2′,C3′-
syn-C3′,C5′-syn diastereoisomer 37. With enantioenriched
aldehyde 26 (er 92:8), exclusive formation of the aldol products
36 and 37 in a 91:9 dr was observed. From that mixture,
alcohol protection and HPLC separation allowed isolation of
38 and 39 in 86% and 6% yields, respectively. As mentioned
above, applying the selective crystallization procedure of 9
would avoid this separation issue, as in this case only aldol
product 36 would be formed.
Cyclization of the Aliphatic Fragment: First Approach.
It was envisaged that the synthesis of the aliphatic fragment
could be completed at this stage by acid-catalyzed t-Bu
deprotection, which would initiate lactone formation that
then could be reduced to the luminacin D lactol ring. The
lactone formation was ﬁrst investigated using the racemic aldol
product 33 as model substrate (Scheme 10). To our surprise,
heating with CSA in toluene led to a product with the t-Bu
ester intact, but in which cyclization toward the epoxide group
had occurred, leading to 41 in excellent yield (81%). When
TFA in DCM was used, the desired lactone formation did
occur, but only 11% of the 43 was isolated. Under these
conditions, the same alternative cyclization leading to a
tetrahydropyran group occurred, even if the resulting product
44 was isolated as the carboxylic acid. Presumably, the slow t-
butyl ester deprotection promoted tetrahydropyran over
lactone formation, and the COOH deprotection leading to
44 could have occurred after the ring formation. Assignment of
the diﬀerent cyclization products was achieved by HMBC and
NOE analyses (see the Supporting Information).
Cyclization under basic conditions was also unsuccessful
(Scheme 11). Treatment of the aldol product 33 with sodium
hydride resulted in the formation of a product 45 in low yield,
Scheme 8. Translation of the Diastereoselective Aldol
Reaction to the Natural Product System
Scheme 9. Evans-Aldol Reaction and Subsequent Separation of the Diastereoisomers
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in which both elimination and oxazolidinone ring-opening had
occurred. Interestingly, when 33 was subjected to lithium
ethylthiolate (see next section), the same elimination product
was obtained in quantitative yield. A mechanism of formation
for this product 45 is proposed: deprotonation of the hydroxyl
group initiates cyclization to the carbamate group, expelling the
primary alkoxide 48, which could then be involved in carbon
dioxide elimination to give 49, possibly via an intramolecular
deprotonation pathway as shown. Finally, amide anion
protonation, either by reaction with 33 or in the workup,
leads to 45. The fact that no elimination/oxazolidinone
opening product such as 45 was formed with lithium
ethylthiolate when the alcohol group was protected (see next
section) is consistent with the proposed mechanism.
Scheme 10. Deprotection and Unexpected Cyclization of the Aldol Product 33
aIsolated in a mixture with 44 (see the Experimental Section).
Scheme 11. Base-Catalyzed Elimination of Aldol Product 33
Scheme 12. Completion of the Aliphatic Fragment Synthesis
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Cyclization of the Aliphatic Fragment: Second
Approach. Given the unsuccessful lactone formation, it was
envisaged to postpone this step until after the introduction of
the aryl fragment (Scheme 12). Hence, oxazolidinone removal
was attempted via thioester formation. At high reagent
concentration, the product 52, resulting from oxazolidinone
opening with lithium ethyl thiolate, was sometimes observed,
alongside with the expected thioester 50. Nevertheless, a fully
chemoselective conversion of TES-protected aldol product 38
to the thioester 50 was achieved in excellent yield using dilute
[EtSLi] conditions. The subsequent palladium-mediated
reduction reaction produced the ﬁnal aldehyde fragment 51.
The yield of the reduction was signiﬁcantly increased by adding
the reagents at 0 °C rather than rt as reported in the previous
procedure (96% vs 66−75%).
Completion of the Synthesis. With the aliphatic fragment
in hand, we pursued our eﬀorts toward the synthesis of the
bromoaryl derivatives 55 and 58, as potential substrates for the
coupling reaction. As depicted in Scheme 13, these two
compounds could be synthesized from the same intermediate
53,10,34,35 and only diﬀer from the choice of protecting groups.
In the ﬁrst case, O-lithiation of 53 and treatment with BOMCl
enabled introduction of the benzyloxy moiety in moderate
yield.10 The obtained 54 was then brominated with NBS to
yield the desired bromoaryl 55. For 58, an O-formylation
reaction was followed by aldehyde reduction, silylation, and
ﬁnally bromination.
The coupling reaction was then carried out in the presence of
t-BuLi and an excess of the bromoaryl derivative (Scheme 14),
leading in each case to the desired product 59 as a mixture of
benzylic alcohol epimers in excellent yield. Pleasingly, the
excess of aromatic compound could be easily recovered by
column chromatography as an inseparable mixture of 57 and
58, and treatment with NBS allowed complete recycling of 58.
The mixture of epimers 59a and 59b was then subjected to
DIBAL-H reduction in order to convert the t-butyl ester to the
corresponding aldehydes 60a−b (Scheme 14). Surprisingly, the
minor benzylic alcohol epimer was found to be unreactive
toward reduction, and aldehydes 60a and 60b were obtained as
a single diastereoisomer, together with the remaining isomeri-
cally pure starting material 59a−b (the alcohol conﬁguration at
C1′ could not be determined). Aldehyde 60b could separated
Scheme 13. Synthesis of Aromatic Fragments
Scheme 14. Formation of Hemiacetals 61
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from 59b by preparative HPLC, and was subsequently
converted to the hemiacetal 61b after treatment with TBAF
and spontaneous cyclization. In the case of 60a, separation
from its starting material was not possible, and the TBAF
treatment was thus applied to the mixture. This led to the
formation of the desired hemiacetal derivative 61a, together
with the residual starting material 62a, with separation now
achieved by column chromatography.
Assuming that the lack of reactivity observed for the minor
epimer 59a (and 59b) was due to conformational restrictions
imposed by the alcohol conﬁguration at C1′, a sequential
oxidation/reduction process toward the formation of 60a was
attempted (Scheme 15). Thus, the benzylic alcohol was
oxidized using Dess−Martin periodinane (DMP) in 73%
yield, and the resulting ketone 63 was then treated with an
excess of DIBAL-H. Although the benzylic ketone in C1′ was
eﬀectively reduced, only a trace amount of the aldehyde 60a
could be observed by NMR. Instead, the compound 59a was
obtained as a single epimer, whose conﬁguration unfortunately
corresponds to that of the previously observed unreactive
isomer. Following this, no further investigation was attempted
on this sequence, and the synthesis was pursued on the major
epimer 61a.
Completion of the luminacin D synthesis was achieved in 2
further steps from the intermediate 61a (Scheme 16). At ﬁrst,
the treatment of 61a using DMP in the presence of NaHCO3
enabled oxidation of the benzylic alcohols to give 64 in
moderate yield. The oxidation step proved cumbersome, with
the best yield (56%) obtained after termination of the reaction
prior to completion (5 min), separation of the product from the
starting material, and resubjecting the remaining starting
material to DMP. A longer reaction time (10 min or 1.5 h)
led to a drop in yield (43% in each case). Finally, subsequent
deprotection provided (−)-luminacin D 1a in 92% yield after
column chromatography, and in 80% after HPLC puriﬁcation.
The ﬁnal sequence was then investigated with the
tribenzylated 61b, as simultaneous deprotection of the benzyl
ethers would enable to complete the synthesis with only bis-
benzylic oxidation left to do (Scheme 17). However, the
hydrogenolysis attempts were associated with numerous
selectivity issues, and 65 was never obtained in a meaningful
yield. It was found that the primary benzylic alcohol could
easily be fully reduced to a methyl group, while the secondary
benzyl alcohol was also found to be labile.
In view of these unexpected results, deprotection conditions
were investigated on a simple model substrate 66 (Scheme 18),
resulting from the coupling reaction between 55 and
propionaldehyde (not shown). It was envisioned that DDQ
Scheme 15. Attempted Sequential Oxidation/Reduction Process
Scheme 16. Completion of the Synthesis from the First Protecting Group Strategy
Scheme 17. Attempted Hydrogenolysis of the Tribenzylated
61b
Scheme 18. DDQ Promoted Debenzylation/Oxidation of
the Secondary Benzyl Alcohol
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.6b00489
J. Org. Chem. 2016, 81, 3818−3837
3827
oxidation of the electron-rich aromatic ring, similar to p-
methoxy benzyl cleavage, would directly lead to the
corresponding C1 aldehyde 68, alongside with BnOH.36,37
However, despite considerable experimentation, this was not
achieved. Surprisingly, this process did yield the ketone 67,
which, though potentially useful for our purposes, was judged
too low-yielding for application on the luminacin D system.
Hence, the hydrogenolysis approach was reinvestigated, using
the same model system.
Given its perceived instability, the secondary benzylic alcohol
group was ﬁrst oxidized to the ketone 69 (Scheme 19).
Manganese dioxide was found ineﬀective at this transformation
on a small scale. The full debenzylation was now achieved
under acidic conditions previously as used by Tatsuda11 to give
the triol 70 in excellent yield. In this reaction, control of the
reaction time was required, as over-reduction to 71 occurred
with longer reaction times, a side reaction not reported by
Tatsuda.11
Finally, these successful reactions were applied to 61b
(Scheme 20). Pleasingly, the initial oxidation to ketone 72
proceeded in quantitative yield, as did the subsequent
debenzylation reaction to triol 73. Luminacin D 1a was then
obtained by a second Dess−Martin oxidation.
3. CONCLUSIONS
A successful second-generation synthesis of enantiopure
(−)-luminacin D is reported in full. The synthetic strategy
relies on a conventional key disconnection to give an aromatic
and aliphatic fragment. The synthesis of the chiral aliphatic
fragment relies on the diastereoselective introduction of the
trisubstituted epoxide subunit, which is achieved by a modiﬁed
de la Pradilla sulfoxide methodology, with the sulfoxide then
becoming a reactive handle for introduction of a formyl group.
A key step is the subsequent diastereoselective allylation of this
formyl group. Initial methodology relying on chelation control
achieved this allylation in very high diastereoselectivity, but
with the wrong relative stereochemistry. Subsequently, diﬀerent
allylation conditions under nonchelation control were found
that achieved this process with the correct relative stereo-
chemistry, in equally excellent de. As a complementary
approach, we also showed that high levels of diastereoselectivity
could be achieved through the reduction of β-keto ester
containing an α-quartenary epoxide center, although this
approach was hampered by the low-yielding acylation reaction
of the sulfoxide derivative.
Completion of the aliphatic fragment was achieved by aldol
reaction involving acyl-oxazolidinones. A ﬁrst approach solely
relying on remote stereocontrol induced by a β-OSiR3 center
Scheme 19. Oxidation/Reduction Sequence
Scheme 20. Completion of the Synthesis from the Second Protecting Group Strategy
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was moderately successful (4:1 de), but the diastereoselection
could be ampliﬁed by the use of a “matched” chiral
oxazolidinone. Installation of the cyclic hemiacetal group
proved not possible at this stage, but was achieved after
coupling with the aromatic fragment. Elaborate ﬁnal depro-
tection investigations using two diﬀerent protecting groups for
the primary benzylic alcohol were required to arrive at a
successful luminacin D synthesis. In spite of the extra oxidation
step required to achieve the synthesis, the second aromatic
protecting strategy described was found more satisfactory in
terms of yield than the ﬁrst route described (40% over 6 steps
vs 22% yield over 5 steps for the ﬁrst route). The successful
enantioselective formation of the trisubstituted epoxide and the
diastereoselective installation of an adjacent chiral alcohol
group will be of general applicability. To the best of our
knowledge, remote stereocontrol by a β-OSiR3 center of an
achiral oxazolidinone based boron enol ether mediated aldol
reaction had not been described before. Overall, this second-
generation synthesis enabled access to the natural product in an
improved yield and a reduced number of steps compared to our
previous approach (5.4%, 17 steps vs 2.6%, 19 steps).
4. EXPERIMENTAL SECTION
General Methods. See the Supporting Information. For atom
numbering in the NMR data, see the corresponding ﬁgures in the
Supporting Information.
Two-Step Procedure to Give Alkenes 8Tol (and (±)-8Ph). To a
solution of t-BuMgCl (1.7 M in THF, 66 mL, 112.8 mmol, 1.5 equiv)
in THF (150 mL) at −78 °C was added 5Tol (19.13 g, 75.2 mmol, 1
equiv) in THF (350 mL) via dropping funnel. The mixture was then
stirred at −78 °C for 1 h before propionaldehyde (97%, 17.2 mL,
233.2 mmol, 3.1 equiv) was added dropwise. The reaction was then
stirred for a further 1.5 h at −78 °C. The reaction mixture was then
allowed to warm up to 0 °C before quenching with a saturated
solution of NH4Cl (200 mL) and H2O (100 mL). The layers were
separated, and the aqueous phase was extracted with Et2O (3 × 250
mL). Organic phases were combined, dried over MgSO4, and
concentrated in vacuo. Puriﬁcation via column chromatography
(petroleum ether/EtOAC 8:2 to 5:5) aﬀorded 24.5 g of the impure
addition product 7Tol as a mixture of diastereoisomers and as a white
solid, which was directly used in the next step. The addition product
7Tol (24.5 g) was dissolved in pyridine (250 mL), and MsCl (17.5 mL,
225.7 mmol, 3 equiv) was added dropwise, by keeping the temperature
between −10 and 0 °C for 40 min. The reaction mixture was stirred
for 16 h without removing the ice bath (T = 10 °C after 16 h), before
quenching with a solution of HCl (1M, 500 mL) dropwise at 0 °C.
The mixture was extracted with Et2O (3 × 600 mL). Organic phases
were combined, dried over MgSO4, and concentrated in vacuo.
Puriﬁcation via column chromatography (petroleum ether/EtOAc
8:2) aﬀorded compound 8Tol as a yellow oil (19.6 g, 88% over 2 steps).
The same procedure was applied with (±)-5Ph (25.7 g, 107.1 mmol,
1 equiv) to aﬀord (±)-8Ph as a yellow oil (22.4 g, 75% over 2 steps)
after column chromatography (petroleum ether/EtOAc 8:2). Data for
8Tol and (±)-8Ph matched those previously reported.
10
Epoxidation of the Enantiopure Alkene 8Tol Using t-BuOOH/n-
BuLi. To a solution of t-BuOOH (5.5 M in decane, dried over MS 4 Å,
5.4 mL, 29.8 mmol, 3 equiv) in THF (290 mL) at −78 °C was added
n-BuLi (2.45 M in hexane, 12.1 mL, 29.8 mmol, 3 equiv) dropwise via
cannula. The resulting solution was stirred at the same temperature for
20 min, before adding a solution of 8Tol (2.92 g, 9.91 mmol, 1 equiv)
in THF (80 mL) dropwise via cannula. The reaction mixture was then
stirred at −78 °C for a further 25 min and was quenched at this
temperature with a saturated solution of Na2S2O3 (200 mL). The
mixture was allowed to warm up to 0 °C and was extracted at this
temperature with EtOAc (3 × 200 mL). Organic phases were
combined, dried over Na2SO4, and concentrated in vacuo, yielding a
mixture of crude epoxides 9Tol and 10Tol (dr syn-9Tol/anti-9Tol/syn-
10Tol/anti-10Tol 86:7:4:3). Puriﬁcation via column chromatography
(pentane/Et2O 8:2 to 6:4) aﬀorded trans-epoxides 9Tol as a white solid
(2.52 g, 82%) and the impure cis-epoxides 10Tol as a colorless oil (68
mg, isolated with minor impurity, <2%). An analytical mixture of 9Tol
was recrystallized from hot pentane (few drops of Et2O added) to give
the pure epoxide syn-9Tol. Analytically pure samples of syn-10Tol and
anti-10Tol were obtained on a small scale for characterization purposes.
Data for 9Tol (mixture of diastereoisomers) matched those
previously reported.10
Data for the Pure syn-9Tol. [α]D +49.2 (c 1.4, CHCl3, 23 °C); mp:
54−56 °C; 1H NMR (400 MHz, CDCl3) δ 7.60 (2H, d, 3JHH 8.1 Hz,
H9, H13), 7.32 (2H, d,
3JHH 8.1 Hz, H10, H12), 3.54 (1H, t,
3JHH 6.4 Hz,
H3), 2.41 (3H, s, H14), 1.81−1.60 (4H, m, H4), 1.34 (9H, m, H7), 1.03
(3H, t, 3JHH 7.5 Hz, H5);
13C NMR (100 MHz, CDCl3) δ 162.4 (C1),
142.5 (C8 or C11), 137.1 (C11 or C8), 129.7 (C9 and C13), 125.6 (C10
and C12), 84.4 (C6), 75.3 (C2), 61.1 (C3), 27.8 (C7), 21.7 (C4), 21.5
(C14) 10.0 (C5) ppm.
Data for 10Tol. IR (neat) 2971 (w, br.), 1743 (m), 1716 (m), 1251
(m), 1096 (s), 1062 (s) cm−1; 1H NMR (400 MHz, CDCl3) δ 7.73
(2H, d, 3JHH 7.8 Hz, H9, H13, anti), 7.62 (2H, d,
3JHH 8.6 Hz, H9, H13,
syn), 7.38−7.28 (4H, m, H10, H12, syn and anti), 3.45 (1H, dd, 3JHH 7.3
Hz, 3JHH 5.5 Hz, H3, syn), 3.26 (1H, dd,
3JHH 7.5 Hz,
3JHH 5.1 Hz, H3,
anti), 2.42 (3H, s, H14, syn), 2.41 (3H, s, H14, anti), 2.32−2.00 (4H, m,
H4, syn and anti), 1.27 (9H, s, syn), 1.244 (9H, s, H7, anti), 1.236 (3H,
t, 3JHH 7.3 Hz, H5, syn), 1.17 (3H, t,
3JHH 7.5 Hz, H5, anti);
13C NMR
(100 MHz, CDCl3) δ 164.7 (C5, anti), 163.2 (C5, syn), 142.9 (C8 or
C11, syn or anti), 141.5 (C8 or C11, syn or anti), 138.3 (C8 or C11, syn or
anti), 136.9 (C8 or C11, syn or anti), 129.7 (C10 and C12, syn or anti),
129.6 (C10 and C12, syn or anti), 127.3 (C9 and C13, anti), 124.7 (C9
and C13, syn), 84.4 (C6, anti), 84.1 (C6, syn), 74.3 (C2, anti), 73.0 (C2,
syn), 65.9 (C3, anti), 65.4 (C3, syn), 27.64 (C7, syn), 27.59 (C7, anti),
21.5 (C14, anti), 21.4 (C14, syn), 21.3 (C4, syn), 19.5 (C4, anti), 10.9
(C5, anti), 10.6 (C5, syn) ppm; MS (ESI
+) (m/z) (peak 1) 311 [M +
H]+, 255 [M − tBu + 2H]+; (peak 2) 311 [M + H]+, 255 [M − tBu +
2H]+; HRMS (ESI+) for C16H22O4S [M + Na]
+ calcd. 333.1131,
found. 333.1136.
Epoxidation of the Alkene (±)-8Ph Using NaH/t-BuOOH. To a
solution of t-BuOOH (5−6 M in decane, 480 μL, 2.4−2.9 mmol, 3.2−
3.9 equiv) in THF (12 mL) at −78 °C was added NaH (60%
dispersion in mineral oil, 75.2 mg, 1.88 mmol, 2.5 equiv) portionwise.
The resulting suspension was allowed to warm up to rt and stirred at
this temperature for 20 min. The suspension was then cooled to −78
°C before adding a solution of (±)-8Ph (211 mg, 0.75 mmol, 1 equiv)
in THF (8 mL) via cannula. The reaction mixture was then stirred at
−78 °C for 20 min and was quenched at this temperature with a
saturated solution of Na2S2O3 (10 mL). The mixture was allowed to
warm up to 0 °C and was extracted at this temperature with Et2O (2 ×
10 mL). Organic phases were combined, dried over Na2SO4, and
concentrated in vacuo, yielding the crude epoxides 9Ph and 10Ph (dr
syn-9Ph/anti-9Ph/syn-10Ph/anti-10Ph 35:4:54:7). Puriﬁcation via col-
umn chromatography (pentane/Et2O 9:1 to 5:5) and preparative
HPLC (pentane/Et2O 7:3) aﬀorded the trans-epoxides 9Ph as a viscous
oil (52 mg, 23%), as well as the cis-epoxides 10Ph as a white solid (117
mg, 53%). An analytical sample of 10Ph was recrystallized from hot
pentane (few drops of Et2O added) to give the pure epoxide (±)-syn-
10Ph.
Data for (±)-(syn+anti)-9Ph matched those previously reported.
10
Data for (±)-(syn+anti)-10Ph. IR (neat) 3080 (w), 2983 (w, br.),
1737 (m), 1373 (m), 1158 (s), 1088 (s); 1H NMR (400 MHz,
CDCl3) δ 7.92−7.80 (2H, m, HAr, anti), 7.79−7.67 (2H, m, HAr, syn),
7.60−7.44 (6H, m, HAr, syn and anti), 3.47 (1H, dd, 3JHH 7.3 Hz, 3JHH
5.4 Hz, H3, syn), 3.29 (1H, dd,
3JHH 7.6 Hz,
3JHH 5.2 Hz, H3, anti),
2.33−2.07 (4H, m, H4, syn and anti), 1.247 (3H, t, 3JHH 7.3 Hz, H5,
syn), 1.240 (9H, s, H7, syn), 1.235 (9H, s, H7, anti), 1.19 (3H, t,
3JHH
7.5 Hz, H5, anti);
13C NMR (100 MHz, CDCl3) δ 164.7 (C1, anti),
163.2 (C1, syn), 141.5 (CqAr, anti), 140.3 (CqAr, syn), 132.3 (CHAr,
anti), 131.1 (CHAr, syn), 129.1 (2C, CHAr, anti), 128.9 (2C, CHAr,
syn), 127.3 (2C, CHAr, anti), 124.7 (2C, CHAr, syn), 84.5 (C6, anti),
84.2 (C6, syn), 74.4 (C2, anti), 73.0 (C2, syn), 65.9 (C3, anti), 65.3 (C3,
syn), 27.6 (C7, syn and anti), 21.3 (C4, anti), 19.5 (C4, syn), 11.0 (C5,
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anti), 10.6 (C5, syn) ppm. MS (ESI
+) (m/z) (peak 1) 241 [M − tBu +
2H]+; (peak 2) 241 [M − tBu + 2H]+;HRMS (ESI+) for C15H20O4S
[M + Na]+ calcd. 319.0975, found. 319.0979.
Data for (±)-syn-10Ph. mp 105−108 °C; 1H NMR (400 MHz,
CDCl3) δ 7.79−7.67 (2H, m, HAr), 7.60−7.44 (3H, m, HAr), 3.47 (1H,
dd, 3JHH 7.2 Hz,
3JHH 5.4 Hz, H3), 2.25−2.07 (2H, m, H4), 1.247 (3H,
t, 3JHH 7.3 Hz, H5), 1.242 (9H, s, H7);
13C NMR (100 MHz, CDCl3) δ
163.2 (C1), 140.4 (CqAr), 131.1 (CHAr), 128.9 (2C, CHAr), 124.7 (2C,
CHAr), 84.2 (C6), 73.0 (C2), 65.4 (C3), 27.6 (C7), 21.4 (C4), 10.6
(C5) ppm.
Oxidation of Sulfoxide Derivatives 10Tol To Give 13. To a solution
of sulfoxides 10Ph (dr syn-10Ph/anti-10Ph ∼ 1:1, 243 mg, 0.78 mmol, 1
equiv) in DCM (5 mL) at rt was added portionwise m-CPBA (77%,
192 mg, 0.86 mmol, 1.1 equiv). The resulting suspension was stirred at
this temperature for 4 h, before quenching with a saturated solution of
Na2S2O3 (5 mL). The layers were separated, and the aqueous phases
were extracted with Et2O (3 × 5 mL). Organic phases were combined,
dried over Na2SO4, and concentrated in vacuo. Puriﬁcation via column
chromatography (pentane/Et2O 8:2) aﬀorded sulfone 13 as a viscous
oil (192 mg, 75%). IR (neat) 2978 (w, br.), 1736 (m), 1331 (m), 1253
(m), 1140 (s, br.) cm−1; 1H NMR (400 MHz, CDCl3) δ 7.87 (2H, d,
3JHH 8.3 Hz, H9 and H13), 7.37 (2H, d,
3JHH 8.0 Hz, H10 and H12), 3.28
(1H, dd, 3JHH 7.5 Hz,
3JHH 5.2 Hz, H3), 2.46 (3H, s, H14), 2.33−2.11
(2H, m, H4), 1.28 (9H, s, H7), 1.19 (3H, t,
3JHH 7.5 Hz, H5);
13C
NMR (100 MHz, CDCl3) δ 162.7 (C1), 145.4 (C8 or C11), 135.9 (C8
or C11), 129.6 (C10 and C12), 128.9 (C9 and C13), 84.9 (C6), 74.3 (C2),
66.3 (C3), 27.5 (C7), 21.7 (C14), 20.4 (C4), 10.9 (C5) ppm; MS (ESI
+)
(m/z) 344 [M + NH4]
+, 349 [M + Na]+; HRMS (ESI+) for
C16H22O5S [M + Na]
+ calcd. 349.1080, found. 349.1079.
Acylation Reaction: Synthesis of Model Substrate 4c. To
compound 9Tol (dr 92:8, 217 mg, 0.70 mmol, 1 equiv), dissolved in
Et2O (4.7 mL), was added methyl butanoate 15 (95 μL, 0.84 mmol,
1.2 equiv) at rt. The mixture was cooled to −78 °C and stirred for 10
min, before adding a solution of t-BuLi (1.9 M in pentane, 880 μL,
1.69 mmol, 2.4 equiv) dropwise for 5 min. The resulting mixture was
stirred at this temperature for 20 min and was quenched at −78 °C
with a saturated solution of NH4Cl (2 mL). The mixture was then
extracted with Et2O (3 × 5 mL). Organic phases were combined, dried
over Na2SO4, and concentrated under reduced pressure (30 °C, <500
mbar) to minimize losses through compound evaporation. Puriﬁcation
via column chromatography (pentane/Et2O 95:5 to 9:1) aﬀorded the
compound 4c as a colorless oil (67 mg, 91% purity with 9% Et2O, 65
mg calculated, 38%, ee ∼ 84%). IR (neat) 2972 (w, br.), 1743 (s), 1716
(s), 1369 (m), 1253 (m), 1163 (m), 1136 (s) cm−1; 1H NMR (400
MHz, CDCl3) δ 3.24 (1H, t,
3JHH 6.1 Hz, H3), 2.58 (1H, dt,
2JHH 17.9
Hz, 3JHH 7.1 Hz, H9), 2.40 (1 H, dt,
2JHH 17.4 Hz,
3JHH 6.8 Hz, H9′),
1.71−1.56 (4H, m, H4, H10), 1.53 (9H, s, H7), 1.10 (3 H, t, 3JHH 7.5
Hz, H5 or H11), 0.92 (3 H, t,
3JHH 7.5 Hz, H11 or H5);
13C NMR (100
MHz, CDCl3) δ 203.0 (C8), 164.6 (C1), 83.5 (C6), 65.9 (C2), 63.1
(C3), 39.5 (C9), 28.0 (C6), 22.7 (C4 or C10), 16.7 (C10 or C4), 13.6
(C5 or C11), 10.1 (C11 or C5) ppm; MS (ESI
+) (m/z) 265 [M + Na]+,
260 [M + NH4]
+, 187 [M − tBu + 2H]+; HRMS (ESI+) for C13H22O4
[M + Na]+ calcd. 265.1416, found. 265.1410.
Diastereoselective Reduction Using L-Selectride (syn-Selective).
To a solution of 4c (129 mg, 0.53 mmol, 1 equiv) in THF (4 mL) at
−78 °C was added L-selectride (1 M solution in THF, 560 μL, 0.56
mmol, 1.05 equiv) dropwise. The mixture was stirred for 30 min at
−78 °C, before quenching with a saturated solution of NH4Cl (2 mL).
The layers were separated, and the aqueous phase was extracted with
Et2O (3 × 5 mL). Organic phases were combined, dried over Na2SO4,
and concentrated in vacuo, yielding the crude alcohol 16 as a mixture
of diastereoisomers (dr 16a/16b 1:9). Puriﬁcation via column
chromatography (petroleum ether/EtOAc 8:2 to 7:3) allowed
isolation of the anti-α-epoxy alcohol 16a (10 mg, 8%) as well as the
syn-α-epoxy alcohol 16b (78 mg, 60%). A mixture of both
diastereoisomers 16 was also obtained (28 mg, 22%, dr 16a/16b
15:85). Overall yield for 16: 116 mg, 90%.
Data for the anti-Product 16a. IR (neat) 3519 (w, br.), 2975 (w,
br.), 1735 (s, br.), 1376 (m), 1266 (s), 1142 (s) cm−1; 1H NMR (400
MHz, CDCl3) δ 3.56 (1H, td,
3JHH 8.1 Hz,
3JHH 3.9 Hz, H8), 3.07 (1H,
t, 3JHH 6.5 Hz, H3), 2.46 (1H, d,
3JHH 7.8 Hz, OH-8), 1.83−1.31 (6H,
m, H4, H9, H10), 1.53 (9H, s, H7), 1.07 (3 H, t,
3JHH 7.3 Hz, H5 or
H11), 0.95 (3 H, t,
3JHH 7.1 Hz, H11 or H5);
13C NMR (100 MHz,
CDCl3) δ 168.2 (C1), 83.3 (C6), 72.5 (C8), 64.6 (C2), 62.4 (C3), 35.7
(C4 or C9 or C10), 28.1 (C7), 21.6 (C4 or C9 or C10), 18.7 (C4 or C9 or
C10), 14.0 (C5 or C11), 10.2 (C11 or C5) ppm; MS (ESI
+) (m/z) 511
[2M + Na]+, 267 [M + Na]+, 189 [M − tBu + 2H]+; HRMS (ESI+) for
C13H24O4 [M + Na]
+ calcd. 267.1567, found. 267.1573.
Data for the syn-Product 16b. IR (neat) 3455 (w, br.), 2968 (m,
br.), 1746 (s), 1372 (s), 1244 (s), 1134 (s) cm−1; 1H NMR (400
MHz, CDCl3) δ 4.16−3.90 (1H, m, H8), 3.19 (1H, t, 3JHH 6.4 Hz, H3),
1.69−1.52 (6H, m, H4, H9, H10), 1.50 (9H, s, H7), 1.05 (3 H, t, 3JHH
7.5 Hz, H5 or H11), 0.95 (3 H, t,
3JHH 7.0 Hz, H11 or H5);
13C NMR
(100 MHz, CDCl3) δ 167.5 (C1), 82.6 (C6), 69.6 (C8), 66.0 (C2), 60.5
(C3), 35.8 (C4 or C9 or C10), 28.0 (C7), 21.4 (C4 or C9 or C10), 18.6
(C4 or C9 or C10), 13.9 (C5 or C11), 10.2 (C11 or C5) ppm; MS (ESI
+)
(m/z) 511 [2M + Na]+, 267 [M + Na]+, 189 [M − t-Bu + 2H]+;
HRMS (ESI+) for C13H24O4 [M + Na]
+ calcd. 267.1567, found.
267.1565.
Diastereoselective Reduction Using NaBH4/CaCl2 (anti-Selective).
To a solution of 4c (120 mg, 0.50 mmol, 1 equiv) in MeOH (4 mL) at
rt was added CaCl2 (111 mg, 1 mmol, 2 equiv). The mixture was
stirred at this temperature for 5 min (dissolution of CaCl2) and was
cooled down to 0 °C. NaBH4 (11 mg, 0.3 mmol, 0.6 equiv) was then
added, and the resulting solution was stirred at this temperature for 20
min, before quenching with a saturated solution of NH4Cl (3 mL).
The mixture was extracted with Et2O (3 × 20 mL). Organic phases
were combined, dried over Na2SO4, and concentrated in vacuo,
yielding the crude alcohol 16 as a mixture of diastereoisomers (dr 16a/
16b 97:3). Puriﬁcation via column chromatography (petroleum ether/
EtOAc 8:2 to 7:3) aﬀorded the anti-product 16a (87 mg, 72%). Data
for the anti-product 16a: see above.
Synthesis of Bromohydrin 17 Using Et3SiH/MgBr2. To a
suspension of magnesium granules (20 mg, 0.85 mmol, 1.6 equiv)
in Et2O (2 mL) at rt was added 1,2-dibromoethane (73 μL, 0.85
mmol, 1.6 equiv). The mixture started to spontaneously reﬂux and was
stirred for approximately 2 h until complete dissolution of the
magnesium. Et2O was then evacuated from the ﬂask under vacuum to
yield a white solid, which was dissolved in DCM (3 mL). Separately, a
ﬂask containing compound 4c (128 mg, 0.53 mmol, 1 equiv) in DCM
(2 mL) was prepared and added to a MgBr2 suspension via syringe. In
another ﬂask, Et3SiH (88 μL, 0.55 mmol, 1.05 equiv) was dissolved in
DCM (2 mL). All ﬂasks were then cooled down at −78 °C and stirred
for 10 min, after which the solution of Et3SiH was then transferred via
syringe, followed by stirring for 2 h at −78 °C. The mixture was then
quenched with a saturated solution of NaHCO3 (2 mL) and diluted
with H2O (10 mL). The layers were separated, and the aqueous phase
was extracted with DCM (3 × 10 mL). Organic phases were
combined, dried over Na2SO4, and concentrated in vacuo. Puriﬁcation
via column chromatography (pentane/Et2O 97:3) aﬀorded the
bromohydrin 17 as a white solid (109 mg, 64%).
Data for 17. IR (neat) 3478 (w, br.), 2956 (w, br.), 1716 (s, br.),
1376 (m), 1281 (m), 1259 (m), 1153 (s), 1123 (s) cm−1; 1H NMR
(400 MHz, CDCl3) δ 4.68 (1H, dd,
3JHH 10.8 Hz,
3JHH 2.2 Hz, H3),
4.19 (1H, s, OH-2, disappeared upon D2O exchange), 2.72 (1H, dt,
2JHH 18.2 Hz,
3JHH 6.9 Hz, H9), 2.45 (1H, dt,
2JHH 18.2 Hz,
3JHH 7.3
Hz, H9′), 1.85−1.70 (1H, m, H4), 1.69−1.53 (3H, m, H4′, H10), 1.57
(9H, s, H7), 1.07 (3 H, t,
3JHH 7.2 Hz, H5), 0.89 (3 H, t,
3JHH 7.3 Hz,
H11);
13C NMR (100 MHz, CDCl3) δ 205.3 (C8), 167.9 (C1), 87.3
(C2 or C6), 85.2 (C6 or C2), 61.3 (C3), 40.3 (C6), 27.7 (C7), 26.7
(C4), 16.7 (C10), 13.5 (C11), 12.8 (C5) ppm; MS (ESI
+) (m/z) 347
[M(81Br) + Na]+, 345 [M(79Br) + Na]+; HRMS (ESI+) for
C13H23
79BrO4 [M + Na]
+ calcd. 345.0672, found. 345.0669.
Synthesis of Bromohydrins 17 and 18 Using NaBH4/MgBr2. To a
suspension of magnesium granules (23 mg, 0.94 mmol, 1.6 equiv) in
Et2O (2 mL) was added 1,2-dibromoethane (80 μL, 0.94 mmol, 1.6
equiv) at rt. The mixture started to spontaneously reﬂux and was
stirred for approximately 2 h until complete dissolution of the
magnesium. Et2O was then evacuated from the ﬂask under vacuum to
yield a white solid, which was dissolved in DCM (3 mL). Separately, a
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ﬂask containing 4c (142 mg, 0.59 mmol, 1 equiv) in DCM (2 mL) was
prepared and added to a MgBr2 suspension via syringe. In another
ﬂask, NaBH4 (23 mg, 0.62 mmol, 1.05 equiv) was dissolved in THF (2
mL). All ﬂasks were then cooled down at −78 °C and stirred for 10
min, after which the solution of NaBH4 was then transferred via
syringe, followed by stirring at this temperature for 1 h. The reaction
mixture was then allowed to warm up to rt, and stirring was continued
for 1 h, before quenching with NaHCO3 (2 mL), and diluting with
H2O (10 mL). The layers were separated, and the aqueous phase was
extracted with DCM (3 × 10 mL). Organic phases were combined,
dried over Na2SO4, and concentrated in vacuo, yielding the crude
bromohydrin 17 and the reduced bromohydrin 18 as a mixture of
diastereoisomers (dr 18a/18b 93:7). Puriﬁcation via column
chromatography (pentane/Et2O 97:3 to 8:2) aﬀorded the bromohy-
drin 17 as a white solid (91 mg, 48%) and the anti-diol 18a as a white
solid (18 mg, 9%), which was recrystallized from hot pentane (few
drops of Et2O added) for characterization purposes.
Data for 18a. mp: 99−102 °C; IR (neat) 3561 (w), 3402 (w, br.),
2964 (w, br.), 1739 (s), 1372 (m), 1153 (s), 1130 (s) cm−1; 1H NMR
(400 MHz, CDCl3) δ 4.47 (1H, dd,
3JHH 11.3 Hz,
3JHH 2.5 Hz, H3),
3.74 (1H, ddd, 3JHH 12.0 Hz,
3JHH 10.5 Hz,
3JHH 2.0 Hz, H8), 3.53 (1H,
s, OH-2), 2.09 (1H, dqd, 2JHH 14.5 Hz,
3JHH 7.2 Hz,
3JHH 2.3 Hz, H4),
1.94 (1H, d, 3JHH 12.0 Hz, OH-8), 1.85−1.70 (2H, m, H4′, H9), 1.69−
1.59 (1H, m, H10), 1.56 (9H, s, H7), 1.48−1.33 (1H, m, H10′), 1.16−
1.01 (1H, m, H9′), 1.11 (3H, t,
3JHH 7.2 Hz, H5), 0.94 (3H, t,
3JHH 7.3
Hz, H11);
13C NMR (100 MHz, CDCl3) δ 172.0 (C1), 84.8 (C2 or
C6), 81.2 (C6 or C2), 73.6 (C8), 63.3 (C3), 34.8 (C9), 28.0 (C7), 24.9
(C4), 19.5 (C10), 13.9 (C11), 12.8 (C5) ppm; MS (ESI
+) (m/z) 349
[M(81Br) + Na]+, 347 [M(79Br) + Na]+; HRMS (ESI+) for
C13H25
79BrO4 [M + Na]
+ calcd. 347.0828, found. 347.0836.
Two-Step Procedure (Acylation/Diastereoselective Reduction) To
Give the α-Epoxy Alcohols (±)-3 and (±)-7. To a solution of (±)-9Ph
(265 mg, 0.89 mmol, 1 equiv) in Et2O (6.0 mL) at rt was added
methyl but-3-enoate 22 (dried over molecular sieves 4 Å, 21%
pentane, 163 mg, 1.43 mmol, 1.6 equiv). The mixture was cooled
down at −78 °C and stirred for 10 min, before adding dropwise a
solution of t-BuLi (1.8 M in pentane, 1.2 mL, 2.13 mmol, 2.4 equiv)
for 5 min. The resulting mixture was stirred −78 °C for 20 min and
was quenched at this temperature with a saturated solution of NH4Cl
(5 mL). The mixture was then extracted with Et2O (3 × 10 mL).
Organic phases were combined, dried over Na2SO4, and concentrated
under reduced pressure (30 °C, <500 mbar) to give the crude β-keto
ester (±)-4b. The crude product (±)-4b was then dissolved in THF
(3 mL), and L-selectride (1 M solution in THF, 0.36 mmol, 360 μL,
0.4 equiv) was added to the mixture dropwise at −78 °C. The resulting
solution was stirred at this temperature for 10 min, before quenching
with a saturated solution of NH4Cl (3 mL). The mixture was extracted
with Et2O (3 × 10 mL), dried over Na2SO4, and concentrated under
reduced pressure, giving the crude α-epoxy allylic alcohols (±)-3 and
(±)-7 as a mixture of diastereoisomers (dr n.d. due to complexity of
the crude mixture, but only the syn-alcohol (±)-3 was observed by 1H
NMR; see the Supporting Information). Puriﬁcation via column
chromatography (pentane/Et2O 9:1 to 6:4) aﬀorded the anti-α-epoxy
alcohol (±)-7 as a colorless oil (2 mg, isolated with unknown
impurities, ∼1% over 2 steps) and the syn-α-epoxy alcohol (±)-3 as a
colorless oil (41 mg, 19% over 2 steps). Data for the syn-product 3 and
the anti-product 7 correspond to those previously reported.10
Hydrogenation of the syn-α-Epoxy Alcohol (±)-3 To Give
(±)-16b. Compound (±)-3 (60 mg, 0.25 mmol, 1 equiv) was
dissolved in EtOAc (4 mL). Pd/C (10 wt %, 26 mg, 26 μmol, 10 mol
%) was added, and the resulting mixture was ﬂushed with H2. Stirring
under an atmosphere of H2 at rt was continued for 24 h, before the
mixture was ﬁltered through a pad of silica and concentrated in vacuo,
yielding the syn-alcohol (±)-16b as a colorless oil (58 mg, 96%). Data
for (±)-16b: see acylation procedure.
Formylation of (±)-9Ph To Give the α-Epoxy Aldehyde (±)-4a
(Small Scale, Optimized Conditions). To compound (±)-9Ph (410
mg, 1.38 mmol, 1 equiv), dissolved in Et2O (9 mL), was added DMF
(dried over molecular sieves 4 Å, 160 μL, 2.07 mmol, 1.5 equiv) at rt.
The mixture was cooled down at −78 °C and stirred for 10 min,
before adding a solution of t-BuLi (1.7 M in pentane, 2.3 mL, 3.86
mmol, 2.8 equiv) dropwise for 15 min. The resulting mixture was
stirred for a further 20 min at −78 °C and was quenched with a
saturated solution of NH4Cl (5 mL). The mixture was then extracted
with Et2O (3 × 10 mL). Organic phases were combined, dried over
Na2SO4, and concentrated under reduced pressure (30 °C, <500
mbar). Puriﬁcation via column chromatography (pentane/Et2O 8:2 to
7:3) aﬀorded the α-epoxy aldehyde (±)-4a as a colorless oil (133 mg,
94% purity with 6% Et2O, 130 mg calculated, 47%). Data for (±)-4a
matched those previously reported.10
Allylation of (±)-4a To Give the α-Epoxy Alcohols (±)-3 and
(±)-7 (Small Scale). Aldehyde (±)-4a (129 mg, 0.64 mmol, 1 equiv)
was dissolved in DCM (2.1 mL) at rt. The solution was cooled to −78
°C, after which allylboronic acid pinacol ester (97%, 135 μL, 0.70
mmol, 1.1 equiv) was added dropwise at −78 °C. The reaction was
allowed to warm up for 14 h (without removing the dry ice bath, T =
10 °C after 14 h). The mixture was then quenched at rt with H2O (5
mL), and stirring was continued for 5 min. The layers were separated,
and the aqueous phase was extracted with Et2O (3 × 10 mL). Organic
phases were combined, dried over Na2SO4, and concentrated in vacuo
to give the crude α-epoxy alcohol as a mixture of diatereoisomers (dr
3/7 > 95:5). Puriﬁcation via column chromatography (pentane/Et2O
8:2 to 7:3) aﬀorded the anti-α-epoxy alcohol (±)-7 as a colorless oil (3
mg, 2%) and the syn-α-epoxy alcohol (±)-3 as a colorless oil (125 mg,
80%). Data for the syn-product (±)-3 and the anti-product (±)-7
correspond to those previously reported.10
Two-Step Procedure (Formylation/Allylation) To Give the α-
Epoxy Alcohols 3 and 7 (Large Scale). To compound 9Tol (dr 92:8,
1.58 g, 5.1 mmol, 1 equiv), dissolved in Et2O (33 mL), was added
DMF (dried over molecular sieves 4 Å, 588 μL, 7.6 mmol, 1.5 equiv).
The mixture was cooled down at −78 °C and stirred for 10 min,
before adding a solution of t-BuLi (1.9 M in pentane, 6 mL, 12.0
mmol, 2.4 equiv) dropwise via syringe pump for 1 h. The resulting
mixture was stirred at −78 °C for 20 min and was quenched at this
temperature with a saturated solution of NH4Cl (25 mL). The mixture
was then extracted with Et2O (3 × 30 mL). The organic phases were
combined, dried over Na2SO4, and concentrated under reduced
pressure (30 °C, <500 mbar). Puriﬁcation via column chromatography
(pentane/Et2O 8:2 to 7:3) aﬀorded the impure α-epoxy aldehyde 4a
as a colorless oil (483 mg, isolated with ca. 30% of Et2O, ee ∼ 84%),
which was used in the next step without further puriﬁcation. The
mixture was dissolved in DCM (8 mL) and cooled down at −78 °C,
after which allylboronic acid pinacol ester (475 μL, 2.53 mmol, 0.5
equiv) was added dropwise. The reaction was then allowed to warm up
for 16 h (without removing the dry ice bath, T ∼ 15 °C after 16 h).
The mixture was then quenched at rt with H2O (8 mL), and stirring
was continued for 5 min. The layers were separated, and the aqueous
phase was extracted with Et2O (3 × 20 mL). Organic phases were
combined, dried over Na2SO4, and concentrated in vacuo to give the
crude α-epoxy alcohols 3 and 7 as a mixture of diastereoisomers (dr
n.d due to complexity of the crude mixture; see copy of 1H NMR
spectrum in the Supporting Information). Puriﬁcation via column
chromatography (pentane/Et2O 8:2 to 7:3) aﬀorded the anti-α-epoxy
alcohol 7 as a colorless oil (11 mg, 1% over 2 steps), and the syn-α-
epoxy alcohol 3 as a colorless oil (400 mg, 33% over 2 steps). The
same procedure was carried out with the phenyl derivative (±)-9Tol
(1.67 g, 5.63 mmol, 1 equiv), giving syn-α-epoxy alcohol (±)-3 as a
colorless oil (454 mg, 33% over 2 steps). Data for the syn-product 3
and the anti-product 7 correspond to those previously reported.10
Synthesis of Aldehyde 26 (2 Steps). Compound 3 (465 mg, 26
mmol, 1 equiv) was dissolved in DCM (19 mL) at rt. The resulting
solution was cooled to 0 °C, after which imidazole (326 mg, 4.79
mmol, 2.5 equiv) was added in one portion, followed by chloro-
triethylsilane (645 μL, 3.84 mmol, 2 equiv) dropwise. The reaction
was then stirred at rt for 16 h, before quenching with a saturated
solution of NH4Cl (20 mL). The layers were separated, and the
aqueous phase was extracted with Et2O (3 × 20 mL). Organic phases
were combined, dried over Na2SO4, and concentrated under reduced
pressure. Puriﬁcation via column chromatography (pentane/Et2O
96:4) aﬀorded the impure protected allyl alcohol (811 mg, 83% purity
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with 17% of TESOH), which was engaged in the next step without
further puriﬁcation. Ozone was bubbled through a solution of impure
protected allyl alcohol (811 mg) in DCM (61 mL) at −78 °C until the
solution became blue (ca. 15 min). The excess of ozone was purged
from the solution by bubbling oxygen through for 20 min.
Triphenylphosphine (587 mg, 2.1 mmol, 1.1 equiv) was then added
dropwise, and stirring was continued for 1 h at −78 °C, before
allowing to warm up to rt over 1 h. The resulting mixture was then
concentrated under vacuum. Puriﬁcation via column chromatography
(crude loaded in DCM; pentane/Et2O 85:15 to 80:20) aﬀorded TES
protected aldehyde 3 as a colorless oil (593 mg, 86% over 2 steps).
The same procedure was carried out with (±)-3 (720 g, 2.97 mmol, 1
equiv), giving aldehyde (±)-26 as a colorless oil (930 mg, 85% over 2
steps). Data for compound 26 correspond to those previously
reported.10
Evans-Aldol Reaction Using the Racemic Aldehyde (±)-26. To a
solution of (S)-4-benzyl-3-pentanoyloxazolidin-2-one (S)-1.93 (1.34 g,
5.12 mmol, 2 equiv) in DCM (4.6 mL) at 0 °C was added Bu2BOTf (1
M in DCM, 5.10 mL, 5.12 mmol, 2 equiv) dropwise to give an orange
solution. The mixture was stirred for 5 min; then DIPEA (890 μL, 5.12
mmol, 2 equiv) was added dropwise and the solution became yellow.
After another 5 min stirring at this temperature, the mixture was
cooled down to −78 °C and transferred via cannula to a solution of
aldehyde (±)-26 (918 mg, 2.56 mmol, 1 equiv) in DCM (5.6 mL) at
−78 °C. The resulting mixture was stirred at this temperature for 3.5
h, then allowed to warm up at 0 °C and stirred for a further 1.5 h. The
reaction mixture was quenched at 0 °C with a mixture of H2O2/
phosphate buﬀer pH 7 (1:1, 30 mL) and was extracted with DCM (3
× 20 mL). Organic layers were combined, dried over Na2SO4, and
concentrated under pressure to give the crude mixture of aldol
products 36 and 37 (dr 36/37 1:1). Puriﬁcation via column
chromatography (pentane/Et2O 8:2 to 5:5) aﬀorded the mixture of
aldol adducts as a colorless viscous oil (1.3 g, 80% purity with 20%
Et2O, 1.26 g calculated, 78%, dr 36/37 36:64). A fraction of the
diastereoisomer 37 was also obtained (208 mg, 86% purity with 14%
Et2O, 203 mg calculated, 13%, trace amount of 36 was detected by
1H
NMR).
Evans-Aldol Reaction Using the Enantioenriched Aldehyde 26.
The same procedure was applied with 26 (er 92:8, 593 mg, 1.65 mmol,
1 equiv) to give a mixture of aldol adducts 36 and 37 as a colorless
viscous oil (943 mg, 88% purity with 12% Et2O, 927 mg calculated,
91%, dr 36/37 92:8). Data for the mixture of 36 and 37 correspond to
those previously reported.10
Synthesis of the Protected Aldol Adducts 38 and 39. From the
Evans Aldol Using the Racemic Aldehyde. To a solution of aldols 36
and 37 (dr 36:64, 1.23 g, 1.98 mmol, 1 equiv) in DCM (20 mL) at 0
°C was added imidazole (336 mg, 3.77 mmol, 2.5 equiv) in one
portion, followed by the dropwise addition of chlorotriethylsilane (670
μL, 3.02 mmol, 2 equiv). The reaction was then stirred for 16 h at rt
before quenching with a saturated solution of NH4Cl (20 mL). The
layers were separated, and the aqueous phase was extracted with Et2O
(3 × 20 mL). Organic phases were combined, dried over Na2SO4, and
concentrated under reduced pressure. Puriﬁcation via column
chromatography (petroleum ether/EtOAC 96:4), followed by HPLC
puriﬁcations (hexane/EtOAc 93:7), aﬀorded 38 (566 mg, 39%), and
39 (728 mg, 50%) as colorless viscous oils. The same procedure was
applied with 37 only (198 mg, 0.32 mmol). Puriﬁcation via column
chromatography (pentane/EtOAC 96:4) aﬀorded the protected 39 as
a colorless resin (233 mg, 99%). Cumulated yield of the two fractions:
38 (728 mg, 43%) and 39 (799 mg, 48%).
From the Evans Aldol Using the Enantioenriched Aldehyde. The
same procedure was applied to a solution of aldol adducts 36 and 37
(dr 36/37 92:8, 935 mg, 1.51 mmol, 1 equiv). Puriﬁcation via column
chromatography (petroleum ether/EtOAC 96:4), followed by HPLC
(hexane/EtOAc 93:7), aﬀorded 38 (950 mg, 86%) and 39 (66 mg,
6%) as colorless viscous oils. Data for 38 correspond to those
previously reported.10 Data for 39: [α]D +25.7 (c 0.88, CHCl3, 23 °C);
IR (neat) 2966 (w, br.), 1772 (m), 1749 (s), 1697 (s), 1455 (s), 1387
(s), 1205 (m), 1092 (m, br.) cm−1; 1H NMR (400 MHz, CDCl3) δ
7.39−7.19 (5H, m, HAr), 4.73−4.61 (1H, m, H14), 4.21−4.12 (3H, m,
H2, H15, H15′), 4.05−3.99 (1H, m, H3), 3.76 (1H, dd, 3JHH 8.6 Hz, 3JHH
4.1 Hz, H5), 3.37 (1H, dd,
2JHH 13.2 Hz,
3JHH 2.9 Hz, CHHPh), 2.96
(1H, t, 3JHH 6.4 Hz, H7), 2.73 (1H, dd,
2JHH 13.2 Hz,
3JHH 10.1 Hz,
CHHPh), 2.19 (1H, ddd, 2JHH 14.8 Hz,
3JHH 7.4 Hz,
3JHH 4.1 Hz, H4),
1.99 (1H, ddd, 2JHH 14.7 Hz,
3JHH 8.7 Hz,
3JHH 4.0 Hz, H4′), 1.89−1.77
(1 H, m, H11), 1.71−1.57 (2H, m, H8, H11′), 1.50 (9H, s, C(CH3)3),
1.53−1.42 (1H, m, H8′), 1.41−1.33 (2H, m, H12, H12′), 1.06 (3H, t,
3JHH 7.5 Hz, H9), 1.02−0.91 (21H, m, H13, CH3TES, CH3′TES), 0.73−
0.58 (12H, m, CH2TES, CH2′TES); 13C NMR (100 MHz, CDCl3) δ
174.8 (C1), 166.9 (C10), 153.1 (C16), 135.6 (CqAr), 129.4 (2C, CHAr),
128.9 (2C, CHAr), 127.3 (CHAr), 82.2 (CMe3), 72.3 (C5), 70.6 (C3),
67.0 (C6), 65.8 (C15), 61.1 (C7), 56.1 (C14), 48.3 (C2), 41.8 (C4), 37.9
(CH2Ph), 30.8 (C11), 28.1 (C(CH3)3), 21.9 (C8), 20.8 (C12), 14.3
(C13), 10.2 (C9), 6.95 (CH3 TES), 6.92 (CH3′TES), 5.0 (CH2TES), 4.9
(CH2′TES) ppm; MS (ESI+) (m/z) 756.5 [M + Na]+; HRMS (ESI+)
for C39H67NO8Si2 [M + Na]
+ calcd. 756.4297; found 756.4287.
Treatment of 33 (as a Mixture with 34) with CSA To Give the
Tetrahydropyran Derivative 41: To a solution of 33 (and 34, dr 33/
34 4:1, 70 mg, 0.107 mmol, 1 equiv) in toluene (5 mL) was added
CSA (2.5 mg, 10.7 μmol, 0.1 equiv) portionwise. The solution was
then stirred and heated to 80 °C for 16 h before the solvent was
evaporated under reduced pressure. Puriﬁcation by column
chromatography (petroleum ether/EtOAc 80/20) aﬀorded 41 as a
colorless oil (56 mg, 81%, contaminated with traces of the
tetrahydropyran derivative resulting from the cyclization of 34).
Data for 41. 1H NMR (400 MHz, CDCl3) δ 7.90−7.62 (4H,m,
HAr‑TBDPS), 7.54−7.31 (6H, m, HAr‑TBDSP), 4.32 (1H, td, 2JHH, 3JHH 8.8




H14′), 4.07 (1H, td,
3JHH 8.2 Hz,
3JHH 5.3 Hz, H2), 3.96−3.95 (1H, br.
s, OH), 3.91 (1H, ddd, 2JHH 11.0 Hz,
3JHH 9.6 Hz,
3JHH 7.1 Hz, H13),
3.82 (1H, dd, 3JHH 11.6 Hz,
3JHH 5.6 Hz, H5), 3.69 (1H, ddd,
2JHH 11.0
Hz, 3JHH 9.1 Hz,
3JHH 6.6 Hz, H13′), 3.28 (1H, ddd,
3JHH 11.4 Hz,
3JHH
8.3 Hz, 3JHH 1.5 Hz, H3), 2.95 (1H, dd,
3JHH 10.6 Hz,
3JHH 1.5 Hz, H7),
2.14 (1H, app. q, J 11.6 Hz, H4), 1.78−1.63 (3H, m, H8, H10), 1.61




2.0 Hz, H4′), 1.24−1.13 (3H, m, H8′, H11), 1.02 (9H, s,
C(CH3)3TBDPS), 0.93 (3H, t,
3JHH 7.6 Hz, H9), 0.86 (3H, t,
3JHH 7.3
Hz, H12);
13C NMR (100 MHz, CDCl3) δ 177.4 (COOtBu), 172.0
(C1), 152.9 (C15), 136.0 (2C, CHAr‑TBDPS), 135.8 (2C, CHAr‑TBDPS),
134.7 (CqAr‑TBDPS), 132.7 (CqAr‑TBDPS), 129.8 (CHAr‑TBDPS), 129.4
(CHAr‑TBDPS), 127.6 (2C, CHAr‑TBDPS), 127.3 (2C, CHAr‑TBDPS), 83.3
((CH3)3Cester), 82.0 (C7), 78.0 (C6), 76.2 (C5), 75.9 (C7), 61.4 (C14),
47.0 (C2), 42.6 (C13), 35.7 (C4), 31.1 (C10), 28.3 (C(CH3)3ester), 26.8
(C(CH3)3TBDPS), 22.2 (C8), 20.3 (C11), 19.3 ((CH3)3CTBDPS), 14.1
(C12), 11.1 (C9) ppm; MS (ESI
+) (m/z) 620.4 [M − tBu + 2H]+,
676.5 [M + Na]+; HRMS (ESI+) for C36H51NO8Si [M + Na]
+ calcd.
676.3276, found. 676.3279.
Treatment of 33 (as a Mixture with 34) with TFA To Give the
Tetrahydropyran Derivative 44 and the Lactone 43. To a solution
of 33 (and 34, dr 33/34 4:1, 38 mg, 58.1 μmol, 1 equiv) in DCM (700
μL) was added TFA (300 μL, excess) dropwise at 0 °C. The solution
was allowed to warm to rt before stirring for 4 h. The reaction solvent
was then evaporated under reduced pressure, removing TFA traces by
azeotropically distilling with portions of toluene (2 × 5 mL).
Puriﬁcation by column chromatography (hexane/EtOAc 60/40),
followed by HPLC (hexane/EtOAc 60/40), aﬀorded 44 (23.2 mg,
67%) as a colorless oil, alongside with a mixture of 43 and 44 (3.8 mg,
11%, ratio 43/44 ∼ 5:1, contaminated with traces of the
tetrahydropyrane derivative resulting from the cyclization of the
minor 34) as colorless oils.
Data for 44. IR (neat) 3480, 2960, 2859, 1779, 1699, 1108 cm−1;
1H NMR (400 MHz, CDCl3) δ 7.76−7.64 (4H, m, HAr‑TBDPS), 7.49−
7.34 (6H, m, HAr‑TBDPS), 4.41−4.26 (2H, m, H14, H14′), 4.16 (1H, td,
3JHH 8.0 Hz,
3JHH 5.3 Hz, H2), 3.98−3.91 (2H, m, H5, H13), 3.87−3.79
(1H, m, H13′), 3.46 (1H, ddd,
3JHH 11.9 Hz, 7.3 Hz,
3JHH 2.0 Hz, H3),
3.14 (1H, dd, 3JHH 10.6 Hz,
3JHH 2.0 Hz, H7), 2.37 (1H, s, OH), 2.06
(1H, dt, 2JHH 13.6 Hz,
3JHH 11.6 Hz, H4), 1.91−1.74 (1H, m, H8),
1.70−1.56 (1H, m, H10), 1.54−1.39 (1H, m, H10′), 1.50 (1H, ddd, 2JHH
13.6 Hz, 3JHH 5.8 Hz,
3JHH 2.0 Hz, H4′), 1.35−1.22 (2H, m, H8′),
1.22−1.11 (2H, m, H11), 1.04 (9H, s, C(CH3)3ester), 0.95 (3H, t, 3JHH
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7.3 Hz, H9), 0.85 (3H, t,
3JHH 7.3 Hz, H12);
13C NMR (100 MHz,
CDCl3) δ 173.9 (COOH), 173.8 (C1), 153.0 (C15), 136.0 (2C,
CHAr‑TBDPS), 135.9 (2C, CHAr‑TBDPS), 134.2 (CqAr‑TBDPS), 132.7
(CqAr‑TBDPS), 129.9 (CHAr‑TBDPS), 129.6 (CHAr‑TBDPS), 127.7 (2C,
CHAr‑TBDPS), 127.6 (2C, CHAr‑TBDPS), 82.2 (C7), 78.3 (C6), 76.3 (C3),
75.8 (C5), 61.7 (C14), 46.0 (C2), 42.7 (C13), 34.6 (C4), 30.7 (C10),
26.7 (C(CH3)3TBDPS), 22.3 (C8), 20.1 (C11), 19.3 ((CH3)3CTBDPS),
14.0 (C12), 10.6 (C9) ppm; MS (ESI
−) (m/z) 596.3 [M − H]−;
HRMS (ESI+) for C32H43NO8Si [M + Na]
+ calcd. 620.2650, found.
620.2651.
Data for 43 (Isolated in a Mixture with 44). 1H NMR (400 MHz,
CDCl3) δ 7.81−7.59 (4H, m, HAr‑TBDPS), 7.54−7.33 (6H, m,




H3), 4.40 (2H, m, H15), 4.36−4.29 (1H, m, H2), 4.06−3.89 (1H, m,
H14), 3.89−3.81 (1H, m, H14′), 3.74 (1H, d, 3JHH 3.2 Hz, H5), 2.81
(1H, t, 3JHH 6.3 Hz, H8), 2.20 (1H, t,
2JHH,
3JHH 12.9 Hz, H4), 1.90−
1.72 (3H, m, H4′, H9, H11), 1.70−1.40 (2H, m, H9′, H11′), 1.38−1.21
(2H, m, H12), 1.09 (9H, s, C(CH3)3‑TBDPS), 0.96 (3H, t,
3JHH 7.6 Hz,
H10), 0.91 (3H, t,
3JHH 7.3 Hz, H13),
13C NMR (100 MHz, CDCl3) δ
173.1 (C1), 167.5 (C7), 136.1 (2C, CHAr‑TBDPS), 135.8 (2C,
CHAr‑TBDPS), 133.4 (CqAr‑TBDPS), 132.1 (CqAr‑TBDPS), 130.0
(CHAr‑TBDPS), 129.9 (CHAr‑TBDPS), 127.8 (2C, CHAr‑TBDPS), 127.7
(2C, CHAr‑TBDPS), 77.2 (C3), 71.6 (C5), 64.6 (C8), 62.3 (C6), 61.8
(C15), 45.8 (C2), 42.7 (C14), 33.5 (C4), 30.2 (C11), 26.8 (C-
(CH3)3ester), 20.3 (C11), 19.9 (C8), 19.3 (C(CH3)3TBDPS), 14.0 (C13),
10.1 (C10) ppm; MS (ESI
+) (m/z) 602.3 [M + Na]+, 643.3 [M + Na +
MeCN]+, 1181.7 [2M + Na]+; HRMS (ESI+) for C32H41NO7Si [M +
Na]+ calcd. 602.2545, found. 602.2548.
Data for 44: see above.
Treatment of 33 with NaH To Give the Elimination Product 45:
To a solution of 33 and 34 (dr 33/34 4:1, 24 mg, 36.1 μmol, 1 equiv)
in THF (1 mL) at −78 °C was added NaH (60% dispersion in mineral
oil, 1.5 mg, 36.1 μmol, 1 equiv). The reaction was stirred for 1 h at
−78 °C before warming to 0 °C during 1 h and stirring for a further
hour at the same temperature. The reaction was then quenched with
H2O (3 mL) before extracting with Et2O (3 × 3 mL). The combined
organic extracts were then washed with brine (2 mL), dried over
NaSO4, and ﬁltered, and the solvent was evaporated under reduced
pressure. Puriﬁcation by column chromatography (petroleum ether/
EtOAc 60/40 to 40/60) aﬀorded 45 as a colorless oil (5.1 mg, 23%).
Data for 45. IR (neat): 3397.2, 3071.3, 2961.7, 2931.4, 2858.7,
1745.8, 1724.4 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.75−7.65 (4H,
m, HAr‑TBDPS), 7.49−7.36 (4H, m, HAr‑TBDPS), 5.92−5.85 (1H, m, NH),
5.88 (4H, t, 3JHH 7.6 Hz, H3), 3.97 (1H, t,
3JHH 7.1 Hz, H5), 3.65 (1H,








H14′), 3.14 (1H, t,
3JHH 6.3 Hz, H7), 2.50 (1H, dt,
2JHH 14.1 Hz,
3JHH
7.1 Hz, H4), 2.45 (1H, dt,
2JHH 14.1 Hz,
3JHH 7.5 Hz, H4′), 2.08−1.86
(2H, m, H11, H11′), 1.72−1.52 (1H, m, H8), 1.48 (9H, s, C(CH3)3ester),
1.44−1.35 (1H, m, H8′), 1.29−1.14 (2H, m, H12), 1.09 (9H, s,
C(CH3)3TBDPS), 1.02 (3H, t,
3JHH 7.6 Hz, H9), 0.76 (3H, t,
3JHH 7.3
Hz, H13);
13C NMR (100 MHz, CDCl3) δ 171.2 (C1), 167.7 (C10),
139.2 (C2), 136.0 (CHAr‑TBDPS), 135.9 (CHAr‑TBDPS), 133.8
(CqAr‑TBDPS), 132.4 (CqAr‑TBDPS), 130.1 (CHAr‑TBDPS), 129.9
(CHAr‑TBDPS), 129.1 (C3), 127.8 (CHAr‑TBDPS), 127.7 (CHAr‑TBDPS),
82.9 ((CH3)3Cester), 73.9 (C5), 66.8 (C6), 63.0 (C15), 61.9 (C7), 43.0
(C14), 33.9 (C4), 29.0 (C11), 28.1 (C(CH3)3ester), 26.9 (C-
(CH3)3TBDPS), 22.0 (C12), 21.7 (C8), 19.5 ((CH3)3CTBDPS), 13.9
(C9), 10.1 (C13) ppm; MS (ESI
+) (m/z): 554.4 [M − tBu + 2H]+,
610.5 [M + H]+, 632.5 [M + Na]+; HRMS (ESI+) for C35H51NO6Si
[M + Na]+ calcd. 632.3378, found. 632.3372.
Synthesis of Thioester 50. See ref 10. Data for byproducts 52
(obtained using nonoptimized conditions, traces of impurity
observed): IR (neat) 3369 (w), 2955 (s), 2876 (m), 1747 (m),
1712 (s), 1677 (s), 1138 (s) cm−1; 1H NMR (400 MHz, CDCl3) δ
ppm 7.39−7.17 (5H, m, HAr), 6.68 (1H, d, 3JHH 8.6 Hz, NH), 4.61−
4.48 (1H, m, H14), 4.28 (1H, dd,
2JHH 11.1 Hz,
2JHH 3.5 Hz, H15), 4.11
(1H, dd, 2JHH 11.1 Hz,
3JHH 4.0 Hz, H15′), 3.86−3.95 (1H, m, H3),
3.53 (1H, dd, 3JHH 9.4 Hz,
3JHH 2.8 Hz, H5) 3.02−2.82 (5H, m,
CH2Bn, H7, H17), 2.35−2.26 (1H, m, H2), 2.19 (1H, ddd, 2JHH 14.8
Hz, 3JHH 9.2 Hz,
3JHH 2.8 Hz, H4), 1.91−1.31 (1H, m, H11) 1.75−1.65
(1H, m, H4′), 1.65−1.50 (1H, m, H8), 1.53 (9H, s, C(CH3)3), 1.42−
1.17 (4H, m, H8′, H11′, H12), 1.38 (3H, t,
3JHH 7.3 Hz, H9 or H13 or
H18), 1.08−0.97 (21H, m, CH3TES, CH3′TES, H9 or H13 or H18), 0.93 (3
H, t, 3JHH 7.1 Hz, H9 or H13 or H18), 0.80−0.61 (12H, m, CH2TES,
CH2′TES) ppm;
13C NMR (100 MHz, CDCl3) δ ppm 172.3 (C1),
170.9 (C16 or C10), 166.4 (C16 or C10), 137.3 (CqAr), 129.2 (2C,
CHAr), 128.5 (2C, CHAr), 126.6 (CHAr), 82.4 (C(CH3)3), 74.2 (C5),
71.3 (C3), 67.20 (C15), 67.17 (C6), 61.4 (C7), 52.1 (C2), 48.8 (C14),
40.4 (C4), 37.4 (CH2Bn), 29.7 (C8 or C11 or C12), 28.1 (C(CH3)3),
25.4 (C17), 21.9 (C8 or C11 or C12), 21.2 (C8 or C11 or C12), 14.9 (C9
or C13 or C18), 14.2 (C9 or C13 or C18), 10.1 (C9 or C13 or C18), 7.0
(CH3TES), 6.9 (CH3′TES), 5.3 (CH2TES), 5.1 (CH2′TES) ppm; MS
(ESI+) (m/z) 818.4 [M + Na]+; HRMS (ESI+) for C41H73NO8SSi2 [M
+ Na]+ calcd. 818.4501, found 818.4482.
Reduction of the Thioester 50 To Give Aldehyde 51. To a solution
of thioester 50 (170 mg, 0.27 mmol, 1 equiv) in DCM (1.5 mL) at 0
°C was added Et3SiH (129 μL, 0.81 mmol, 3 equiv) and Pd/C (10 wt
%, 57 mg, 54 μmol, 20 mol %) in one portion. The mixture was then
stirred for 20 min at rt, before adding DCM (0.75 mL). The
suspension was stirred for a further 18 h, before ﬁltering through
Celite, washing with DCM (15 mL), and concentrating under reduced
pressure. Puriﬁcation via column chromatography (pentane/Et2O 98:2
to 95:5) aﬀorded compound 51 as a colorless oil (145 mg, 96%). Data
for 51 correspond to those previously reported.10
Formylation of 53 To Give Aldehyde 56. To a solution of 53 (3.0
g, 8.2 mmol, 1 equiv) in Et2O (25 mL) at rt was added TMEDA (1.9
mL, 13.0 mmol, 1.58 equiv), and the solution was cooled to 0 °C.
Following this, n-BuLi (1.6 M in hexanes, 8.1 mL, 13.0 mmol, 1.58
equiv) was added dropwise and the mixture was stirred at 0 °C for 15
min. DMF (1.50 mL, 19.0 mmol, 2.3 equiv) was then added dropwise
at 0 °C, and the reaction mixture was stirred for a further hour. The
reaction mixture was allowed to warm to rt slowly and was quenched
with H2O (20 mL). The mixture was extracted with ether (2 × 20
mL). The combined organic phases were washed with brine (20 mL),
dried over MgSO4, and concentrated in vacuo. Puriﬁcation via column
chromatography (hexane/Et2O 90:10) aﬀorded compound 56 as a
white solid (1.33 g, 43%).
Data for 56. IR (neat) 3032, 2954, 2866, 1685, 1591 cm−1; 1H
NMR (400 MHz, CDCl3) δ 10.59 (1H, s, H12), 7.54−7.29 (11H, m,
HAr, H3, H6), 6.80 (1H, d,
3JHH 8.6 Hz, H4), 5.18 (2H, s, H10 or H11),
4.94 (2H, s, H10 or H11), 2.41 (2H, d,
3JHH 7.2 Hz, H7), 1.90 (1H, tspt,
3JHH 7.2 Hz,
3JHH 6.6 Hz, H8), 0.86 (6H, d,
3JHH 6.6 Hz, H9, H9′) ppm;
13C NMR (100 MHz, CDCl3) δ 189.6 (C12), 160.0 (C1 or C5), 158.8
(C1 or C5), 137.13 (C3), 137.09 (CqAr), 136.3 (CqAr), 128.7 (2C,
CHAr), 128.51 (C2), 128.48 (2C, CHAr), 128.2 (2C, CHAr), 128.1 (2C,
CHAr), 127.2 (2C, CHAr), 119.4 (C6), 108.5 (C4), 77.3 (C10 or C11
(DEPT 135)), 70.9 (C10 or C11), 38.6 (C7), 29.1 (C8), 22.4 (C9 and
C9′) ppm; MS (EI) (m/z) 90.9 [Bn]
+ (100%), 257.0 [M − Bn + 2H −
CO]+ (2%), 347.0 [M − CO + H]+ (4%); HRMS (ESI+) for
C25H26O3 [M + Na]
+ calcd. 397.1774, found. 397.1771.
Reduction of Aldehyde 56 and TBS-Protection To Give 57. To a
solution of aldehyde 56 (1.0 g, 2.7 mmol, 1 equiv) in THF (20 mL) at
rt was added NaBH4 (220 mg, 5.9 mmol, 2.2 equiv) in one portion.
The reaction mixture was stirred for 1.5 h at this temperature, before
quenching with H2O (10 mL), followed by dropwise addition of HCl
(0.5 M, 5 mL). The mixture was diluted with Et2O (10 mL), and the
phases were separated. The aqueous phase was re-extracted with Et2O
(2 × 25 mL), and the combined organic phases were washed with a
saturated solution of NH4Cl (20 mL). The combined organic phases
were dried over Na2SO4 and concentrated in vacuo, to give the
corresponding alcohol as a pale oil which was used without further
puriﬁcation.
The crude alcohol (1.0 g, 2.7 mmol, 1 equiv) was then dissolved in
DMF (25 mL) at rt, after which TBSCl (0.48 g, 3.2 mmol, 1.2 equiv)
was added dropwise, followed by imidazole (0.43 g, 6.4 mmol, 2.4
equiv) in one portion. The reaction mixture was stirred for 1 h before
quenching with H2O (20 mL), and stirred for an additional 15 min.
The mixture was extracted with Et2O (3 × 25 mL), the combined
organic phases were washed with brine (20 mL), dried over Na2SO4,
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and concentrated in vacuo. Puriﬁcation via column chromatography
(hexane/Et2O 80:20) aﬀorded compound 57 as a yellow oil (1.18 g,
90% over 2 steps).
IR (neat) 3031 (w), 2952 (m), 2866 (m), 1600 (m), 1483 (m),
1347 (m) cm−1; 1H NMR (400 MHz, CDCl3) δ 7.53−7.30 (10H, m,
HAr), 7.05 (1H, d,
3JHH 8.4 Hz, H3), 6.70 (1H, d,
3JHH 8.4 Hz, H4),
5.09 (2H, s, H11 or H10), 5.05 (2H, s, H11 or H10), 4.84 (2H, s, H12),
2.46 (2H, d, 3JHH 7.2 Hz, H7), 1.93 (1H, tspt,
3JHH 7.2 Hz,
3JHH 6.6 Hz
H8), 0.89 (6H, d,
3JHH 6.7 Hz, H9, H9′), 0.84 (9H, s, H15), −0.01 (6H,
s, H13, H13′);
13C NMR (101 MHz, CDCl3) δ 157.4 (C1 or C5), 156.7
(C5 or C1), 138.2 (CqAr), 137.3 (CqAr), 130.5 (C3), 128.4 (3 or 4C,
CHAr), 127.8 (CHAr), 127.7 (2 or 3C, CHAr), 127.44 (C2 or C6),
127.41 (2C, CHAr), 122.9 (C6 or C2), 107.9 (C4), 76.8 (C10 or C11),
70.5 (C10 or C11), 55.2 (C12), 39.2 (C8), 29.3 (C7), 26.0 (C15), 22.6
(C9 and C9′), 18.4 (C14), −5.4 (C13 and C13′) ppm; MS (ESI+) (m/z)
513 [M + Na]+; HRMS (ESI+) for C31H42O3Si [M + Na]
+ calcd.
513.2975; found. 513.2976.
Bromination To Yield the Aromatic Derivative 58. To a solution
of protected triol 57 (998 mg, 2.0 mmol, 1 equiv) in dry CHCl3 (20
mL) at rt was added NBS (724 mg, 4.0 mmol, 2 equiv), and the
reaction mixture was stirred overnight in the dark. At completion, the
reaction mixture was concentrated in vacuo and extracted with Et2O
(30 mL) and H2O (30 mL). The aqueous layer was re-extracted with
ether (30 mL), and the combined organic phases were dried over
Na2SO4 and concentrated in vacuo. Puriﬁcation via column
chromatography (hexane/Et2O 97:3) aﬀorded compound 58 as a
yellow solid (1.11 g, 96%).
IR (neat) 2954 (s), 2928 (m), 2856 (w), 1497 (w), 1448 (m) cm−1;
1H NMR (400 MHz, CDCl3) δ 7.60−7.53 (2H, m with the presence
of 3JHH 7.0 Hz, HAr and/or H3), 7.49−7.31 (9H, m, HAr and/or H3),
5.13 (2H, s, H11 or H10), 5.00 (2H, s, H11 or H10), 4.77 (2H, s, H12),
2.45 (2H, d, 3JHH 7.2 Hz, H7), 1.94 (1H, tspt,
3JHH 7.2 Hz,
3JHH 6.6 Hz,
H8), 0.90 (6H, d,
3JHH 6.7 Hz, H9, H9′), 0.84 (9H, s, H15), −0.01 (6H,
s, H13, H13′);
13C NMR (100 MHz, CDCl3) δ 156.6 (C1 or C5), 153.8
(C1 or C5), 137.6 (CqAr), 137.3 (CqAr), 134.3 (C3), 133.1 (C4 or C6),
130.0 (C4 or C6), 128.5 (2C, CHAr), 128.3 (2C, CHAr), 127.9 (CHAr),
127.8 (CHAr), 127.7 (2C, CHAr), 127.1, (2C, CHAr), 112.5 (C2), 76.8
(C10 or C11), 76.1 (C10 or C11), 55.8 (C12), 39.0 (C7), 29.3 (C8), 25.9
(C15), 22.5 (C9 and C9′), 18.1 (C14), −5.4 (C13 and C13′) ppm; MS
(ESI+) (m/z) 593 [M(81Br) + Na]+, 591 [M(79Br) + Na]+; HRMS
(ESI+) C31H41
79BrO3Si [M + Na]
+ calcd. 591.1901, found. 591.1882.
Coupling Reaction between 51 and 58. To a solution of
bromoaryl 58 (427 mg, 0.75 mmol, 3 equiv) in THF (2.5 mL) at
−78 °C was added t-BuLi (1.86 M in pentane, 400 μL, 0.75 mmol, 3
equiv) dropwise. The mixture was stirred at this temperature for 10
min, after which a solution of aldehyde 51 (142 mg, 0.25 mmol, 1
equiv) in THF (9 mL), was added at −78 °C, and the ﬂask was
washed with THF (2 mL). The resulting solution was stirred at −78
°C for 45 min, before quenching at this temperature with H2O (10
mL). The mixture was then allowed to warm up to rt before extracting
with Et2O (3 × 20 mL). The organic layers were combined, dried over
Na2SO4, and concentrated under reduced pressure. Puriﬁcation via
column chromatography (pentane/Et2O 9:1) gave the coupling
product 59a as a mixture of epimers (245 mg, 92%, dr 63:37),
alongside with an inseparable mixture of aromatic derivatives 57 and
58 (206 mg, 57/58 70:30). A preparative HPLC (pentane/EtOAc
98:2) was then performed on an analytical mixture of the pure 59a (80
mg), which allowed separation of the major epimer of 58a (52 mg)
and the minor epimer of 58a (27 mg) for characterization purposes
(major isomer eluted ﬁrst). The conﬁguration at C1 was not
determined.
Data for 58a (Major Isomer). [α]D +18.6 (c 1.26, CHCl3, 22 °C);
1H NMR (400 MHz, CDCl3) δ 7.52−7.29 (11H, m, HAr), 5.22−5.17
(2H, m, H1, CHHPh), 5.15−5.09 (2H, m, CH2Ph), 5.00−4.93 (1H,
m, CHHPh), 4.83−4.72 (2H, m, H17), 4.07−3.99 (1H, m, H3), 3.43
(1H, d, 3JHH 1.3 Hz, OH-1), 3.32 (1 H, dd,
3JHH 7.0 Hz,
3JHH 5.1 Hz,
H5), 2.71 (1H, t,
3JHH 6.4 Hz, H7), 2.55 (1H, dd,
3JHH 13.3 Hz,
3JHH
7.4 Hz, H14), 2.39 (1 H, dd,
3JHH 13.4 Hz,
3JHH 7.1 Hz, H14′), 2.23 (1
H, dt, 2JHH 14.7 Hz,
3JHH 7.4 Hz, H4), 2.09−1.95 (2H, m, H4′, H15),
1.83−1.75 (1H, m, H2), 1.63−1.40 (2H, m, H8, H11), 1.48 (9H, s,
C(CH3)3 ester), 1.39−1.16 (4H, m, H8′, H11′, H12, H12′), 1.00−0.85
(27H, m, H9, H16, H16′, CH3TES), 0.80 (9H, s, C(CH3)3TBS), 0.73 (3H,
t, 3JHH 6.6 Hz, H13), 0.69−0.55 (12H, m, CH2TES), −0.03 (3H, s,
CH3TBS), −0.06 (3H, s, CH3′TBS); 13C NMR (100 MHz, CDCl3) δ
166.4 (C10), 156.4 (COBn), 154.1 (COBn), 138.1 (CqAr), 137.7
(CqAr), 132.6 (CqAr), 130.6 (CqAr), 129.0 (CHAr), 128.4 (2C, CHAr),
128.3 (2C, CHAr), 127.7 (CHAr), 127.5 (CHAr), 127.2 (2C, CHAr),
127.1 (CqAr), 126.9 (2C, CHAr), 82.1 ((CH3)3Cester), 77.3 (CH2Ph
(DEPT 135)), 76.6 (CH2Ph), 75.9 (C3), 74.9 (C5), 71.4 (C1), 67.0
(C6), 61.1 (C7), 55.4 (C17), 47.3 (C2), 41.3 (C4), 39.3 (C14), 29.5
(C15), 28.0 (C(CH3)3 ester), 25.8 (C(CH3)3TBS), 24.7 (C11), 23.0 (C12),
22.6 (C16 or C16′), 22.4 (C16 or C16′), 21.9 (C8), 18.0 ((CH3)3CTBS),
14.6 (C13), 10.1 (C9), 6.9 (CH3TES, CH3′TES), 5.36 (CH2TES), 4.88
(CH2′TES), −5.5 (CH3TBS), −5.7 (CH3′TBS) ppm; MS (ESI+) (m/z)
1071.65 [M + Na]+.
Data for 58a (Minor Isomer). [α]D +13.6 (c 0.69, CHCl3, 22 °C);
IR (neat) 3477 (w, br.), 2958 (s, br.), 1749 (m,br.), 1471 (w), 1356
(m), 1245 (m), 1095 (s) cm−1 ; 1H NMR (400 MHz, CDCl3) δ 7.50−
7.28 (11 H, m, HAr), 5.19−5.12 (2H, m, H1, CHHPh), 5.11 (1H, d,
3JHH 4.5 Hz, CHHPh), 5.08 (1H, d,
3JHH 4.3 Hz, CHHPh), 5.00−4.94
(1H, m, CHHPh), 4.92−4.89 (1H, m, OH-1), 4.81 (1H, d, 3JHH 9.6
Hz, H17), 4.75 (1 H, d,
3JHH 9.7 Hz, H17′), 4.10 (1H, app. d, J 9 Hz, H3
or H5), 3.52 (1H, dd,
3JHH 9.4 Hz,
3JHH 1.5 Hz, H5 or H3), 2.80 (1H, t,
3JHH 6.3 Hz, H7), 2.59 (1H, dd,
2JHH 13.5 Hz,
3JHH 7.0 Hz, H14), 2.44−
2.31 (2H, m, H4, H14′), 2.09−1.91 (3H, m, H2, H4′, H15), 1.66−1.57
(1H, m, H8), 1.53−1.45 (1H, m, H8′), 1.36 (9H, s, C(CH3)3 ester),
1.22−1.10 (1H, m, H11 or H12), 1.08−0.93 (24H, m, H9,, H11′, H12′,
CH3TES, H12 or H11), 0.90 (3H, d,
3JHH 6.5 Hz, H16 or H16′), 0.89 (3H,
d, 3JHH 6.6 Hz, H16 or H16′), 0.79 (9H, s, C(CH3)3TBS), 0.77−0.60
(15H, m, H13, CH2TES), −0.075 (3H, s, CH3TBS), −0.079 (3H, s,
CH3TBS);
13C NMR (100 MHz, CDCl3) δ166.3 (C10), 156.7 (COBn),
155.1 (COBn), 138.2 (CqAr), 138.0 (CqAr), 132.3 (CqAr), 131.2 (CqAr),
130.0 (CHAr), 128.34 (2C, CHAr), 128.28 (2C, CHAr), 127.5 (CHAr),
127.4 (CHAr), 127.3 (CqAr), 127.2 (2C, CHAr), 126.9 (2C, CHAr), 82.1
((CH3)3Cester), 77.7 (CH2Ph), 76.5 (CH2Ph), 74.5 (C3 or C5), 73.6
(C3 or C5), 70.1 (br. s, C1), 67.2 (C6), 61.4 (C7), 55.4 (C17), 49.2
(C2), 39.4 (C4 or C14), 39.2 (C4 or C14), 29.8 (C12 or C11), 29.2 (C15),
27.9 (C(CH3)3ester), 25.8 (C(CH3)3TBS), 22.6 (C16 or C16′), 22.5 (C16
or C16′), 21.7 (C8), 21.0 (C11 or C12), 17.9 ((CH3)3CTBS), 14.1 (C13),
10.2 (C9), 6.9 (CH3 TES, CH3′TES), 5.4 (CH2TES), 5.1 (CH2TES),-5.5
(CH3TBS),-5.6 (CH3′TBS) ppm; MS (ESI
+) (m/z) 1071.66 [M + Na]+.
Reduction/Deprotection Leading to Hemiacetal 61a, and
Deprotected Ester 62a. To a solution of 60a (107 mg, 0.10 mmol,
dr 67:33, 1 equiv) in toluene (3.2 mL) at −78 °C was added DIBAL-H
(1 M in heptane, 400 μL, 0.40 mmol, 4 equiv) dropwise. The resulting
mixture was stirred for 1 h at this temperature, before quenching with
MeOH (3 mL) at −78 °C. The solution was allowed to warm up to 0
°C, after which H2O (3 mL) was added, and the resulting mixture was
stirred for a further 1 h at 0 °C. The mixture was ﬁltered through a pad
of Celite and washed with EtOAc (24 mL). The layers were separated,
and the aqueous phase was extracted with EtOAc (5 mL). The
combined organic layers were dried over anhydrous Na2SO4 and
concentrated under reduced pressure. Puriﬁcation via column
chromatography (pentane/Et2O 95:5 to 9:1), followed by preparative
HPLC (hexane/Et2O 9:1), gave a mixture of aldehyde 60a and starting
material 59a (86 mg), which was used in the next step without further
puriﬁcation.
The mixture (86 mg) was then dissolved in THF (3 mL), and
TBAF (1 M in THF, 520 μL, 0.52 mmol, 5.2 equiv) was added
dropwise at 0 °C. The resulting solution was stirred for 1 h at 0 °C.
Then, the mixture was allowed to warm up to rt, and stirring was
continued for 2.5 h at this temperature, before evaporating under
reduced pressure. Puriﬁcation via column chromatography (pentane/
acetone 8:2 to 7:3) gave the hemiacetal 61a as a single epimer and as a
colorless oil (35 mg, isolated with 5% of 62a, 54% over 2 steps), as
well as an impure mixture of deprotected ester 62a, which was
repuriﬁed by preparative HPLC (hexane/acetone 7:3) to give the pure
62a as a colorless oil (10.9 mg, 15% over 2 steps, dr 85:15).
Data for 61a. [α]D +31.8 (c 0.23, CHCl3, 21 °C); IR (neat) 3408
(m, br.), 2955 (s, br.), 2353 (m, br.), 1458 (s), 1212 (m), 1098 (s),
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1019 (s) cm−1; 1H NMR (400 MHz, CDCl3) δ 7.53−7.35 (10H, m,
HAr), 7.32 (1H, s, HAr), 5.11 (1H, d,
3JHH 5.8 Hz, H1), 5.05 (1H, d,
2JHH 10.9 Hz, CHHPh), 5.00−4.92 (3H, m, CHHPh, CH2Ph), 4.84
(1H, s, H7), 4.73 (2H, app. d,
3JHH 4.9 Hz, H17), 4.02 (1H, td,
3JHH
11.3 Hz, 3JHH 5.1 Hz, H3 or H5), 3.85 (1 H, d,
3JHH 11.4 Hz, H5 or
H3), 3.35−3.28 (1H, m, OH-7), 3.24 (1H, dd, 3JHH 7.2 Hz, 3JHH 5.8
Hz, H8), 2.60 (1H, dd,
2JHH 13.2 Hz,
3JHH 7.1 Hz, H14), 2.52 (1 H, dd,
2JHH 13.3 Hz,
3JHH 7.3 Hz, H14′), 2.29 (1 H, t,
3JHH 5.5 Hz, OH-17),
2.25−2.18 (1H, m, OH-1), 2.06−1.94 (1H, m, H15), 1.76−1.67 (1H,
m, H4), 1.67−1.48 (6H, m, H2, H4′, H9, H9′, H11, H11′), 1.37−1.19
(2H, m, H12), 1.06 (3H, t,
3JHH 7.5 Hz, H10), 0.92 (3H, d,
3JHH 6.8 Hz,
H16 or H16′), 0.91 (3H, d,
3JHH 6.8 Hz, H16 or H16′), 0.82 (3H, t,
3JHH
7.3 Hz, H13);
13C NMR (100 MHz, CDCl3) δ 156.1 (COBn), 152.8
(COBn), 137.2 (CqAr), 136.6 (CqAr), 133.0 (CqAr), 131.9 (CqAr), 129.1
(CHAr), 128.7 (4C, CHAr), 128.6 (CHAr), 128.4 (2C, CHAr), 128.2
(CHAr), 127.7 (2C, CHAr), 127.4 (CqAr), 94.3 (C7), 77.7 (CH2Bn),
76.5 (CH2Bn), 71.1 (C1), 69.8 (C3 or C5), 63.0 (C5or C3), 61.8 (C6),
59.6 (C8), 56.3 (C17), 49.0 (C2), 39.4 (C14), 37.3 (C4), 29.3 (C15),
26.6 (C11), 23.3 (C12), 22.6 (C16 or C16′), 22.4 (C16 or C16′), 20.6
(C9), 14.5 (C13), 10.6 (C10); MS (ESI
+) (m/z) 657 [M + Na]+;
HRMS (ESI+) for C38H50O8 [M + Na]
+ calcd. 657.3398, found
657.3385.
Data for 62a (Mixture of Diastereoisomers). IR (neat) 3395 (m,
br.), 2966 (s, br.), 1724 (m), 1457 (m), 1370 (m), 1247 (m), 1098 (s)
cm−1; 1H NMR (400 MHz, CDCl3) δ 7.53−7.33 (20H, m, HAr, major
and minor), 7.32 (1H, s, HAr, minor), 7.26 (1H, s, HAr, major), 5.11−
5.08 (1H, m, H1, minor), 5.04 (2H, d,
2JHH 11.1 Hz, CHHPh, major
and minor), 5.00−4.92 (6H, m, CH2Ph, CHHPh, major and minor),
4.75 (2H, app. d, 3JHH 5.9 Hz, H17, major), 4.41 (1H, ddd,
3JHH 9.1 Hz,
3JHH 6.5 Hz,
3JHH 3.0 Hz, H3 or H5, major), 4.31−4.20 (2H, m, H3 or
H5, major and minor), 4.17−4.09 (1H, m, H3 or H5, minor), 3.73−3.65
(1H, m, OH-3 or OH-5, major), 3.27 (1H, t, 3JHH 6.4 Hz, H7, major
and minor), 3.14−3.08 (1H, m, OH, minor), 3.04−2.97 (1H, d, 3JHH
8.8 Hz, OH-5 or OH-3, major), 2.86 (1H, br. d, 3JHH 9.5 Hz, OH,
minor), 2.66−2.42 (3H, m, H14, H14′,OH-17, major), 2.06−1.89 (3H,
m, H2, H4, H15, major), 1.69−1.51 (3H, m, H4′, H8, H8′, OH-1, major),
1.48 (9H, s, (CH3)3C, major), 1.44 (9H, s, (CH3)3C, minor), 1.32−
1.10 (2H, m, H12), 1.09−0.98 (2H, m, H11), 1.06 (3H, t, 3JHH 7.7 Hz,
H9, major), 0.908 (3H, d,
3JHH 6.3 Hz, H16 or H16′, major), 0.904 (3H,
d, 3JHH 6.2 Hz, H16 or H16′, major), 0.73 (3 H, t,
3JHH 7.1 Hz, H9,
major); 13C NMR (100 MHz, CDCl3) δ 167.8 (C10), 156.4 (COBn),
153.3 (COBn), 137.1 (CqAr), 136.6 (CqAr), 132.4 (CqAr), 131.7 (CqAr),
129.3 (CHAr), 128.72 (CHAr), 128.66 (br. s, CHAr), 128.60 (CHAr)
128.53 (CHAr), 128.48 (CHAr), 128.3 (CHAr), 128.1 (CHAr), 127.8
(CHAr), 127.7 (CHAr), 127.6 (CqAr), 82.6 ((CH3)3C), 77.6 (CH2Bn),
76.4 (CH2Bn), 72.6 (C1 or C3 or C5, minor), 72.4 (C1 or C3 or C5,
minor), 71.0 (C1), 70.4 (C3), 67.4 (C5), 65.9 (C6), 59.8 (C7), 56.5
(C17), 48.1 (C2), 39.3 (C14), 34.6 (C4), 29.2 (C15), 29.1 (C11), 28.0
(C(CH3)3), 27.9 (C(CH3)3, minor), 22.6 (C16), 22.5 (C16′), 21.4
(C8), 20.7 (C12), 14.1 (C13), 10.3 (C9) ppm; MS (ESI
+) (m/z) (peak
1) 729 [M + Na]+, (peak 2) 729 [M + Na]+; HRMS (ESI+) for
C42H58O9 [M + Na]
+ calcd. 729.3973; found 729.3964.
Bis-benzylic Oxidation of 61a To Give 64. To a solution of 61a
(18.5 mg, 29.1 μmol, 1 equiv) in DCM (2 mL) at 0 °C were
successively added NaHCO3 (24.4 mg, 29.1 μmol, 10 equiv) and
Dess−Martin periodinane (25.3 mg, 59.7 μmol, 2.05 equiv). The
mixture was stirred at rt for 5 min, before ﬁltering through a pad of
silica (pentane/Et2O 5:5) to give 8 mg of impure keto aldehyde 64. A
mixture of mono-oxidized product and starting material 61a (9.1 mg,
ca. 2:1 respectively) was also isolated. The mixture of starting material
61a and mono-oxidized product (9.1 mg) was redissolved in DCM (1
mL), and NaHCO3 (13 mg) was added at 0 °C, followed by Dess−
Martin periodinane (8 mg). The resulting suspension was then stirred
at rt for 8 min, before ﬁltering through a pad of silica (pentane/Et2O
5:5) to give 3 mg of impure keto aldehyde, which was combined with
the ﬁrst fraction and puriﬁed via column chromatography (pentane/
Et2O 5:5) to give the pure benzyl protected luminacin D 64 (10.3 mg,
56%) as a colorless oil.
Data for 64. IR (neat) cm−1 3432 (br., m), 2957 (m, br.), 1690 (s),
1556 (m), 1556 (m), 1369 (m), 1094 (s, br.); 1H NMR (400 MHz,
CDCl3) δ 10.33 (1H, s, H17), 7.52−7.33 (11H, m, HAr), 5.07 (1H, d,
2JHH 10.3 Hz, CHHPh), 5.04 (1H, d,
2JHH 10.1 Hz, CHHPh), 4.98
(1H, d, 2JHH 11.5 Hz, CHHPh), 4.95 (1H, d,
2JHH 11.3 Hz, CHHPh),
4.66 (1H, d, 3JHH 2.3 Hz, H7), 4.39 (1H, ddd,
3JHH 11.7 Hz,
3JHH 4.8
Hz, 3JHH 1.3 Hz, H3), 4.11 (1H, td,
3JHH 11.6 Hz,
3JHH 4.9 Hz, H5),
3.36 (1H, dt, 3JHH 8.7 Hz,
3JHH 4.3 Hz, H2), 3.22 (1H, t,
3JHH 6.5 Hz,
H8), 2.49 (2H, d,
3JHH 7.2 Hz, H14), 2.47 (1H, d,
3JHH 2.8 Hz, OH-7),
2.01−1.85 (3H, m, H4, H11, H15), 1.59−1.45 (4H, m, H4′, H9, H9′,
H11′), 1.44−1.29 (1H, m, H12), 1.29−1.15 (1H, m, H12′), 1.03 (3H, t,
3JHH 7.5 Hz, H10), 0.92−0.85 (9H, m, H13, H16, H16′); 13C NMR (100
MHz, CDCl3) δ 203.6 (C17), 189.1 (C1), 161.3 (COBn), 156.7
(COBn), 136.1 (CqAr), 135.81 (CqAr), 135.77 (CHAr), 132.7 (CqAr),
132.4 (CqAr), 128.9 (2C, CHAr), 128.68 (CHAr), 128.65 (2C, CHAr),
128.60 (2C, CHAr), 128.5 (CHAr), 128.2 (2C, CHAr), 124.3 (CqAr),
94.3 (C7), 80.2 (CH2Bn), 78.2 (CH2Bn), 67.5 (C3), 62.8 (C5), 61.5
(C6), 59.5 (C8), 54.9 (C2), 38.7 (C14), 36.8 (C4), 29.1 (C15), 28.1
(C11), 22.5 (C16 or C16′), 22.3 (C16 or C16′), 20.9 (C8), 20.5 (C12),
14.3 (C13), 10.5 (C10) ppm; MS (ESI
+) (m/z) 653 [M + Na]+; HRMS
(ESI+) for C38H46O8 [M + Na]
+ calcd. 653.3085; found 653.3091.
Hydrogenolysis of 64 To Give (−)-Luminacin D 1a. The benzyl
protected luminacin D 1a (12.6 mg, 20.5 μmol, 1 equiv) was dissolved
in EtOAc (8 mL). Pd/C (10 wt %, 5 mg, 21 μmol, 10 mol %) was
added, and the resultant mixture was ﬂushed with H2. Stirring under
an atmosphere of H2 was continued at rt for 24 h, before the mixture
was ﬁltered through a pad of silica and concentrated in vacuo.
Puriﬁcation by column chromatography (hexane/EtOAc 70:30),
followed by preparative HPLC (hexane/EtOAc 65:35), aﬀorded
(−)-Luminacin D 1a as a pale yellow residue (7.2 mg, 80%). Data for
1a correspond to those previsouly reported.10,38
DDQ-Oxidation of 66 To Give Compound 67. To a solution of 66
(55 mg, 0.11 mmol, 1 equiv) in DCM/H2O (9:1, 5 mL) was added
DDQ (119 mg, 0.524 mmol, 5 equiv). The reaction was then heated to
reﬂux for 24 h, after which the reaction was portioned between a
saturated solution of NaHCO3 (5 mL) and DCM (5 mL); the
separated aqueous phase was then extracted with a further portion of
DCM (5 mL). The combined organic extracts were then scrubbed
with brine (5 mL), dried over Na2SO4, and ﬁltered, and the solvent
was evaporated under reduced pressure. The crude was puriﬁed by
column chromatography (petroleum ether/Et2O 80:20) to give 67 as a
colorless oil (22 mg, 48%). The product was further puriﬁed by HPLC
(hexane/acetone 90:10) to give 9.8 mg (22%) of pure product.
Data for 67. 1H NMR (400 MHz, CD3CN) δ 7.57−7.32 (11H, m,
HAr, H3), 4.99 (2H, s, CH2Ph), 4.95 (2H, s, CH2Ph), 4.67 (2H, d,
3JHH
4.9 Hz, H13), 3.08 (1H, t,
3JHH 5.1 Hz, OH), 2.96 (2H, q,
3JHH 7.3 Hz,
H11), 2.54 (2H, d,
3JHH 7.2 Hz, H7), 2.01−1.85 (1H, m, H8), 1.08 (3H,
t, 3JHH 7.3 Hz, H12), 0.88 (6H, d,
3JHH 6.8 Hz, H9, H9′) ppm;
13C NMR
(100 MHz, CDCl3) δ 204.5 (C10), 161.1 (COBn), 157.0 (COBn),
139.0 (CqAr), 138.6 (CqAr), 132.8 (C2), 132.5 (C3), 131.7 (C6), 130.6
(C4), 130.0 (CHAr), 129.9 (CHAr), 129.7 (CHAr), 129.6 (CHAr), 129.6
(CHAr), 129.4 (CHAr), 79.7 (CH2Bn), 78.1 (CH2Bn), 55.7 (C13), 40.2
(C7), 36.9 (C11), 30.4 (C8), 23.1 (C9 and C9′), 9.1 (C12) ppm; MS
(ESI+) (m/z) 455 [M + Na]+, 496.3 [M + Na + MeCN]+.
DMP-Oxidation of 66 To Give Compound 69. To a solution of 66
(70 mg, 0.133 mmol, 1 equiv) in DCM (5 mL) were sequentially
added NaHCO3 (56 mg, 0.67 mmol, 5 equiv) and Dess−Martin
periodane (68 mg, 0.160 mmol, 1.2 equiv). The mixture was stirred at
rt for 1 h before quenching with a saturated solution of Na2SO3 (3
mL) and water (5 mL). The mixture was then extracted with portions
of DCM (3 × 10 mL). The combined extracts were washed with
NaHCO3 (3 × 7.5 mL), dried over Na2SO4, and ﬁltered, and the
solvent was evaporated under reduced pressure. The crude residue was
then puriﬁed by column chromatography (petroleum ether/Et2O
80:20) to yield 69 as a colorless oil (64 mg, 92%).
Data for 69. IR (neat) 3031, 2955, 2869, 1680, 1588 cm−1; 1H
NMR (400 MHz, CDCl3) δ 7.51−7.32 (15H, m, HAr), 7.28 (1H, s, H3,
overlapped with the solvent peak), 5.04 (2H, s, CH2Ph), 5.02 (2H, s,
CH2Ph), 4.68 (2H, s, CH2Ph), 4.56 (2H, s, CH2Ph), 3.00 (2H, q,
3JHH
7.4 Hz, H11), 2.54 (2H, d,
3JHH 7.1 Hz, H7), 1.99 (1H, tspt,
3JHH 7.1
Hz, 3JHH 6.6 Hz, H8), 1.15 (3H, t,
3JHH 7.1 Hz, H12), 0.92 (6H, d,
3JHH
6.6 Hz, H9, H9′) ppm;
13C NMR (100 MHz, CDCl3) δ 203.8 (C10),
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.6b00489
J. Org. Chem. 2016, 81, 3818−3837
3835
160.6 (COBn), 156.4 (COBn), 137.9 (CqAr), 137.5 (CqAr), 137.0
(CqAr), 131.8 (C3), 131.5 (C4), 130.2 (C2), 128.7 (CHAr), 128.7
(CHAr), 128.5 (CHAr), 128.4 (CHAr), 128.0 (CHAr), 127.9 (CHAr),
127.7 (CHAr), 127.6 (CHAr), 127.3 (CHAr), 126.2 (C6), 78.8
(CH2Bn), 77.0 (CH2Bn), 73.3 (CH2Bn), 62.7 (C13), 39.1 (C7), 35.9
(C11), 29.2 (C8), 22.5 (C9 and C9′), 8.5 (C12) ppm; MS (ESI
+) (m/z)
545 [M + Na]+; HRMS (ESI+) for C35H38O4 [M + Na]
+ calcd.
545.2662, found. 545.2667.
Hydrogenolysis of 69 (Short Reaction Time). To a solution of 69
(95 mg, 0.182 mmol, 1 equiv) in THF (285 μL) was added Pd/C in
one portion under N2, followed by acetic acid dropwise (15 μL). The
reaction was then purged with H2 by bubbling through the suspension,
adding THF periodically to combat evaporation. After 2.5 h under H2,
the mixture was ﬁltered through Celite and washed with THF (3 × 3
mL). The solvent was then evaporated and the crude was puriﬁed by
column chromatography (petroleum ether/Et2O 80:20) to yield the
triol 70 as a colorless oil (36 mg, 78%).
Data for 70. IR (neat) 3403, 3213, 2964, 2914, 1606 cm−1; 1H
NMR (400 MHz, CDCl3) δ 13.02 (1H, s, OH), 9.00 (1H, s, OH),
7.40 (1H, s, H3), 5.09 (1H, d,
3JHH 5.1 Hz, H13), 2.95 (1H, q,
3JHH 7.1
Hz, H11), 2.43 (2H, d,
3JHH 7.1 Hz, H7), 2.33 (1H, t,
3JHH 5.3 Hz,
OH13), 1.92 (1H, tspt,
3JHH 7.1 Hz,
3JHH 6.6 Hz, H8), 1.23 (3H, t,
3JHH
7.3 Hz, H12), 0.93 (6H, d,
3JHH 6.6 Hz, H9, H9′) ppm;
13C NMR (100
MHz, CDCl3) δ 205.7 (C10), 162.1 (COH), 159.7 (COH), 131.4
(C3), 120.6 (C2), 111.9 (C6), 110.4 (C4), 58.8 (C13), 38.8 (C11), 31.1
(C7), 28.5 (C8), 22.4 (C9 and C9′), 8.7 (C12) ppm; MS (ESI
+) (m/z)
316. [M + Na + MeCN]+, 527. [2M + Na]+; HRMS (ESI−) for
C14H20O4 [M − H]− calcd. 251.1289, found 251.1285.
Hydrogenolysis of 69 (Extended Reaction Time). To a solution of
69 (60 mg, 0.115 mmol, 1 equiv) in THF (0.95 mL) was added Pd/C
in one portion under N2, followed by acetic acid dropwise (50 μL).
The reaction was then purged with H2 by bubbling through the
suspension, adding THF periodically to combat evaporation. After 20
h under H2, the mixture was ﬁltered through Celite and washed with
THF (3 × 3 mL); the solvent was then evaporated to yield a mixture
of 71 and 70 (28 mg, >99%, 71/70 98:2).
Data for 71. IR (neat) 3457, 2955, 2869, 1624, 1464 cm−1; 1H
NMR (400 MHz, CDCl3) δ 12.97 (1H, s, OH), 7.36 (1H, s, H3), 5.35
(1H, br. s., OH), 2.97 (2H, q, 3JHH 7.2 Hz, H11), 2.44 (2H, d,
3JHH 7.1
Hz, H7), 2.14 (3H, s, H13), 1.89 (CH2CHMe2, tspt,
3JHH 7.1 Hz,
3JHH
6.8 Hz, H8), 1.24 (3H, t,
3JHH 7.2 Hz, H12), 0.94 (6H, d,
3JHH 6.8 Hz,
H9, H9′) ppm;
13C NMR (100 MHz, CDCl3) δ 205.7 (C10), 161.1
(COH), 158.4 (COH), 129.5 (C3), 118.3 (C2), 112.7 (C6), 110.3
(C4), 39.2 (C7), 31.2 (C11), 28.7 (C8), 22.4 (C9 and C9′), 8.7 (C13),
7.5 (C12) ppm; MS (ESI
−) (m/z) 235 [M − H]−, HRMS (ESI+) for
C14H20O3 [M + H]
+ calcd. 237.1485, found. 237.1490.
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